<SEC-DOCUMENT>0001513162-21-000010.txt : 20210122
<SEC-HEADER>0001513162-21-000010.hdr.sgml : 20210122
<ACCEPTANCE-DATETIME>20210122171503
ACCESSION NUMBER:		0001513162-21-000010
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210122
DATE AS OF CHANGE:		20210122

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMERICA INC
		CENTRAL INDEX KEY:			0000073290
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				952645573
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-239980
		FILM NUMBER:		21547062

	BUSINESS ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
		BUSINESS PHONE:		9496452111

	MAIL ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NMS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19871130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR MEDICAL SYSTEMS INC
		DATE OF NAME CHANGE:	19830216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR INSTRUMENTS INC
		DATE OF NAME CHANGE:	19720508
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>prospectussupplement.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<head> <title>Prospectus Supplement</title></head> <body vlink=purple link=blue style=TEXT-JUSTIFY-TRIM:punctuation lang=EN-IN> <div style=page:WordSection1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:right; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=right><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>Filed Pursuant to Rule 424(b)(5)<br>Registration No. 333-<a name=Section_1 />239980</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:8pt 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><b><u><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black; LINE-HEIGHT:120%' lang=EN-US>PROSPECTUS SUPPLEMENT</font></u></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>(To Prospectus dated September 30, 2020)</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:12pt 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><b><font style='FONT-SIZE:14pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>$15,000,000</font></b></p><p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:12pt 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center></p> <p style=page:WordSection7 align=center><img width=3549 height=600 style="HEIGHT:50px; WIDTH:252px" src=logo.jpg></p><p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:12pt 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:12pt 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><b><font style='FONT-SIZE:14pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>Common Stock</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 2pt; TEXT-AUTOSPACE:; TEXT-INDENT:36pt' align=justify><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>This prospectus supplement relates to the issuance and sale of up to $15,000,000 of shares of our common stock from time to time through our sales agent, B. Riley Securities, Inc., or B. Riley Securities, the &#147;sales agent.&#148; These sales, if any, will be made pursuant to the terms of the At Market Issuance Sales Agreement as amended, or the sales agreement, between us and the sales agent.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 10pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>Our common stock is traded on the Nasdaq Capital Market, or the NASDAQ, under the symbol &#147;BMRA.&#148; On January 20, 2021, the closing sale price of our common stock on NASDAQ was $6.16 per share.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 2pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>Sales of shares of our common stock under this prospectus supplement, if any, may be made by any method deemed to be an &#147;at the market offering&#148; as defined in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 2pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 2pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>The sales agent is not required to sell any specific number of shares of our common stock. The sales agent has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between the sales agent and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. The sales agent will be entitled to compensation under the terms of the sales agreement at a commission rate equal to up to 3.0% of the gross proceeds of the sales price of common stock that they sell. The net proceeds from any sales under this prospectus supplement will be used as described under &#147;Use of Proceeds.&#148; The proceeds we receive from sales of our common stock, if any, will depend on the number of shares actually sold and the offering price of such shares.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 2pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 2pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>In connection with the sale of common stock on our behalf, B. Riley Securities will be deemed to be an underwriter within the meaning of the Securities Act, and its compensation as the sales agent will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to B. Riley Securities with respect to certain liabilities, including liabilities under the Securities Act. </font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US> <hr width=100% size=2 noshade style=COLOR:black align=center> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:12pt 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:120%; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>Investing in our securities involves a high degree of risk. You should read carefully and consider the information contained in and incorporated by reference under &#147;</font></b><font lang=EN-US><a href=#RF><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%'>Risk Factors</font></b></a></font><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>&#148; beginning on page S-5 of this prospectus, and the risk factors contained in other documents incorporated by reference.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:12pt 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:120%; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font></b></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US> <hr width=100% size=2 noshade style=COLOR:black align=center> </font></div> <div align=center> <table width=679 bordercolor=transparent style="WIDTH:509.15pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:24.75pt> <td width=237 style="HEIGHT:24.75pt; WIDTH:177.7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:2pt 0cm; TEXT-AUTOSPACE:'><b></b>&nbsp;</p></td> <td width=11 style="HEIGHT:24.75pt; WIDTH:8.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:2pt 0cm; TEXT-AUTOSPACE:'>&nbsp;</p></td> <td width=182 style="HEIGHT:24.75pt; WIDTH:136.35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=center><b><font style='FONT-SIZE:16pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>B. Riley Securities</font></b></p></td> <td width=12 style="HEIGHT:24.75pt; WIDTH:9pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:2pt 0cm; TEXT-AUTOSPACE:'>&nbsp;</p></td> <td width=237 style="HEIGHT:24.75pt; WIDTH:178.05pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:right; MARGIN:2pt 13.05pt 2pt 0cm; TEXT-AUTOSPACE:' align=right><b></b>&nbsp;</p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:15pt 0cm 0pt; LINE-HEIGHT:138%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:138%' lang=EN-US>The date of this prospectus supplement is January 22, 2021</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:ideograph-numeric' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:ideograph-numeric'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 7pt; TEXT-AUTOSPACE:' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US><a name=TOC>TABLE OF CONTENTS</a></font></b></p> <div align=center> <table width=667 bordercolor=transparent style="WIDTH:500pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:13pt> <td width=625 style="HEIGHT:13pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:2pt 0cm; TEXT-AUTOSPACE:'><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>PROSPECTUS SUPPLEMENT</font></b></p></td> <td width=47 style="HEIGHT:13pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:0cm"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:2pt 0cm; TEXT-AUTOSPACE:'>&nbsp;</p></td></tr> <tr style=HEIGHT:13pt> <td width=625 style="HEIGHT:13pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:2pt 0cm; TEXT-AUTOSPACE:'>&nbsp;</p></td> <td width=47 style="BORDER-TOP:0px; HEIGHT:13pt; BORDER-RIGHT:0px; WIDTH:35pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:center; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Page</font></b></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:4pt 0cm 4pt 10pt; TEXT-AUTOSPACE:; TEXT-INDENT:-10pt'><font lang=EN-US><a href=#ATPS><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>ABOUT THIS PROSPECTUSSUPPLEMENT</font></a></font><u></u></p></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>S-1</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:4pt 0cm 4pt 10pt; TEXT-AUTOSPACE:; TEXT-INDENT:-10pt'><u><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:blue' lang=EN-US><a href=#PSS>PROSPECTUS SUPPLEMENT SUMMARY</a></font></u></p></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>S-3</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:4pt 0cm 4pt 10pt; TEXT-AUTOSPACE:; TEXT-INDENT:-10pt'><u><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:blue' lang=EN-US><a href=#RF>RISK FACTORS</a></font></u></p></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>S-5</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:4pt 0cm 4pt 10pt; TEXT-AUTOSPACE:; TEXT-INDENT:-10pt'><u><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:blue' lang=EN-US><a href=#NRFLS>NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></font></u></p></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>S-6</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:4pt 0cm 4pt 10pt; TEXT-AUTOSPACE:; TEXT-INDENT:-10pt'><u><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:blue' lang=EN-US><a href=#UOP>USE OF PROCEEDS</a></font></u></p></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>S-7</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:4pt 0cm 4pt 10pt; TEXT-AUTOSPACE:; TEXT-INDENT:-10pt'><u><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:blue' lang=EN-US><a href=#Dilution>DILUTION</a></font></u></p></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>S-8</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:4pt 0cm 4pt 10pt; TEXT-AUTOSPACE:; TEXT-INDENT:-10pt'><u><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:blue' lang=EN-US><a href=#DP>DIVIDEND POLICY</a></font></u></p></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>S-9</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:4pt 0cm 4pt 10pt; TEXT-AUTOSPACE:; TEXT-INDENT:-10pt'><u><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:blue' lang=EN-US><a href=#DOCS>DESCRIPTION OF CAPITAL STOCK</a></font></u></p></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>S-10</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:4pt 0cm 4pt 10pt; TEXT-AUTOSPACE:; TEXT-INDENT:-10pt'><u><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:blue' lang=EN-US><a href=#POD>PLAN OF DISTRIBUTION</a></font></u></p></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>S-13</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:4pt 0cm 4pt 10pt; TEXT-AUTOSPACE:; TEXT-INDENT:-10pt'><u><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:blue' lang=EN-US><a href=#LM>LEGAL MATTERS</a></font></u></p></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>S-14</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:4pt 0cm 4pt 10pt; TEXT-AUTOSPACE:; TEXT-INDENT:-10pt'><u><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:blue' lang=EN-US><a href=#Experts>EXPERTS</a></font></u></p></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>S-14</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:4pt 0cm 4pt 10pt; TEXT-AUTOSPACE:; TEXT-INDENT:-10pt'><u><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:blue' lang=EN-US><a href=#WYCFMI>WHERE YOU CAN FIND MORE INFORMATION</a></font></u></p></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>S-14</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:4pt 0cm 4pt 10pt; TEXT-AUTOSPACE:; TEXT-INDENT:-10pt'><u><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:blue' lang=EN-US><a href=#IOCDBR>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</a></font></u></p></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>S-15</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:3pt 0cm 7pt; TEXT-AUTOSPACE:'>&nbsp;</p> <div align=center> <table width=667 bordercolor=transparent style="WIDTH:500pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:13pt> <td width=625 style="HEIGHT:13pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:2pt 0cm; TEXT-AUTOSPACE:'><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>ACCOMPANYING PROSPECTUS</font></b></p></td> <td width=47 style="HEIGHT:13pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:0cm"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:2pt 0cm; TEXT-AUTOSPACE:'>&nbsp;</p></td></tr> <tr style=HEIGHT:13pt> <td width=625 style="HEIGHT:13pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:2pt 0cm; TEXT-AUTOSPACE:'>&nbsp;</p></td> <td width=47 style="BORDER-TOP:0px; HEIGHT:13pt; BORDER-RIGHT:0px; WIDTH:35pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:center; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Page</font></b></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=bottom><font style=FONT-SIZE:10pt>ABOUT THIS PROSPECTUS</font></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>1</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=bottom><font style=FONT-SIZE:10pt>SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION</font></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>2</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=bottom><font style=FONT-SIZE:10pt>ABOUT THE COMPANY</font></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>3</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=bottom><font style=FONT-SIZE:10pt>RISK FACTORS</font></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>5</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=bottom><font style=FONT-SIZE:10pt>USE OF PROCEEDS</font></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>6</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=bottom><font style=FONT-SIZE:10pt>DESCRIPTION OF CAPITAL STOCK</font></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>7</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=bottom><font style=FONT-SIZE:10pt>SELLING STOCKHOLDERS</font></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>10</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=bottom><font style=FONT-SIZE:10pt>PLAN OF DISTRIBUTION</font></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>12</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=bottom><font style=FONT-SIZE:10pt>LEGAL MATTERS</font></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>14</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=bottom><font style=FONT-SIZE:10pt>EXPERTS</font></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>14</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=bottom><font style=FONT-SIZE:10pt>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</font></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>15</font></p></td></tr> <tr style=HEIGHT:18pt> <td width=625 style="HEIGHT:18pt; WIDTH:469pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=bottom><font style=FONT-SIZE:10pt>WHERE YOU CAN FIND MORE INFORMATION</font></td> <td width=47 style="HEIGHT:18pt; WIDTH:35pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:right; MARGIN:2pt 0cm; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>16</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:5pt 0cm 0pt; LINE-HEIGHT:138%; TEXT-AUTOSPACE:'><b></b>&nbsp;</p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div></div><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US><br clear=all style=PAGE-BREAK-BEFORE:none></font> <div style=page:WordSection2> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US><a name=ATPS>ABOUT THIS PROSPECTUS SUPPLEMENT</a></font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:10pt 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:120%; TEXT-AUTOSPACE:; TEXT-INDENT:41pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>This document is part of a registration statement that was filed with the Securities and Exchange Commission, or the SEC, using a &#147;shelf&#148; registration process and consists of two parts. The first part is the prospectus supplement, including the documents incorporated by reference herein, which describes the specific terms of this offering. The second part, the accompanying prospectus, including the documents incorporated by reference therein, provides more general information. In general, when we refer only to the prospectus, we are referring to both parts of this document combined. Before you invest, you should carefully read this prospectus supplement, the accompanying prospectus, all information incorporated by reference herein and therein, as well as the additional information described under the heading&nbsp;&#147;Where You Can Find More Information.&#148;&nbsp;These documents contain information you should carefully consider when deciding whether to invest in our common stock.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:10pt 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:120%; TEXT-AUTOSPACE:; TEXT-INDENT:41pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>This prospectus supplement may add, update or change information contained in the accompanying prospectus. To the extent there is a conflict between the information contained in this prospectus supplement and the accompanying prospectus, you should rely on information contained in this prospectus supplement, provided that if any statement in, or incorporated by reference into, one of these documents is inconsistent with a statement in another document having a later date, the statement in the document having the later date modifies or supersedes the earlier statement. Any statement so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:10pt 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:120%; TEXT-AUTOSPACE:; TEXT-INDENT:41pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>You should rely only on the information contained in this prospectus supplement, the accompanying prospectus, any document incorporated by reference herein or therein, or any free writing prospectuses we may provide to you in connection with this offering. Neither we nor the sales agent has authorized anyone to provide you with any different information. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide to you.&nbsp;The information contained in this prospectus supplement, the accompanying prospectus, and in the documents incorporated by reference herein or therein is accurate only as of the date such information is presented. Our business, financial condition, results of operations and prospects may have changed since that date.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:10pt 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:120%; TEXT-AUTOSPACE:; TEXT-INDENT:41pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>This prospectus supplement and the accompanying prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the shares of common stock to which it relates, nor do this prospectus supplement and the accompanying prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:10pt 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:120%; TEXT-AUTOSPACE:; TEXT-INDENT:41pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>Unless otherwise indicated, information contained in or incorporated by reference into this prospectus concerning our industry and the markets in which we operate, including market opportunity, market position and competitive landscape, is based on information from our management&#146;s estimates, as well as from industry publications, surveys and studies conducted by third parties. Management estimates are derived from publicly available information, our knowledge of our industry, and assumptions based on such information and knowledge, which we believe to be reasonable. In addition, while we believe that information contained in industry publications, surveys and studies&nbsp;has been obtained from reliable sources, the accuracy and completeness of such information is not guaranteed, and we have not independently verified any of the data contained in these third-party sources.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:10pt 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:120%; TEXT-AUTOSPACE:; TEXT-INDENT:41pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>This prospectus supplement and the accompanying prospectus, and any documents incorporated by reference herein or therein, include statements that are based on various assumptions and estimates that are subject to numerous known and unknown risks and uncertainties. Some of these risks and uncertainties are described under the heading&nbsp;&#147;Risk Factors&#148; beginning on page S-5 of this prospectus supplement and in the section titled &#147;Risk Factors&#148; in our most recent Quarterly Report on Form 10-Q and in our most recent Annual Report on Form 10-K, each of which is incorporated by reference into the prospectus. These and other important factors could cause our future results to be materially different from the results expected as a result of, or implied by, these assumptions and estimates.&nbsp;You should read the information contained in this prospectus supplement and the accompanying prospectus, and the documents incorporated by reference herein and therein, completely and with the understanding that future results may be materially different and worse from what we expect.&nbsp;See the information included under the heading &#147;Note Regarding Forward-Looking Statements.&#148;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:10pt 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style=FONT-SIZE:10pt face="Times New Roman">S-1</font> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:10pt 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:120%; TEXT-AUTOSPACE:; TEXT-INDENT:41pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>Securities offered pursuant to the registration statement to which this prospectus supplement relates may only be offered and sold if not more than three years have elapsed since September 30, 2020, the initial effective date of the registration statement, subject to the extension of this period in compliance with applicable SEC rules.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:10pt 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:120%; TEXT-AUTOSPACE:; TEXT-INDENT:41pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>We note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreement, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:10pt 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:120%; TEXT-AUTOSPACE:; TEXT-INDENT:41pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>Unless otherwise indicated or the context otherwise requires, the terms &#147;Company,&#148; &#147;Biomerica,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Biomerica, Inc., a Delaware corporation, and its predecessors and consolidated subsidiaries.</font></p></div><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US><br clear=all style=PAGE-BREAK-BEFORE:none></font></b> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; TEXT-ALIGN:center; MARGIN:10pt 0in 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%'>S-2</font></p> <hr><DIV style="PAGE-BREAK-BEFORE: always"></DIV><div style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; TEXT-ALIGN:center; MARGIN:10pt 0in 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; LINE-HEIGHT:120%' lang=EN-IN> </font></div> <DIV style= 'border-style: solid;'><p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%'><a name=PSS>PROSPECTUS SUPPLEMENT SUMMARY</a></font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><i></i>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; TEXT-ALIGN:justify;MARGIN:0in 0in 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><i><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%'>The following is a summary of selected information contained elsewhere or incorporated by reference. It does not contain all of the information that you should consider before buying our securities. You should read this prospectus in its entirety, including the information incorporated by reference herein and therein.</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%'>Company Overview</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; BACKGROUND:white; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 12pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:0.5in'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>We are a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (physicians' offices and over-the-counter through drugstores and online) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. Our diagnostic test kits are used to analyze blood, urine or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 12pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:0.5in'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>Our primary focus is the research and development of disruptive, patented diagnostic-guided therapy (&#147;DGT&#148;) products to treat gastrointestinal diseases, such as irritable bowel syndrome, and other inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. If these DGT products prove effective in their clinical trials, and are ultimately cleared for sale by the U.S. FDA, management believes the revenue potential to the Company is significant.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 12pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:0.5in'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>The products we currently sell are primarily focused on gastrointestinal diseases, food intolerances, diabetes and certain esoteric tests.&nbsp; These diagnostic test products utilize immunoassay technology. These products are CE marked and/or sold for diagnostic use where they are registered by each country&#146;s regulatory agency.&nbsp; In addition, some products are cleared for sale in the U.S. by the FDA.&nbsp; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0pt 0in; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:0.5in'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>We continue to see progress in completing the testing required to attain FDA clearance for our patented&nbsp;InFoods&#174; IBS&nbsp;DGT product that is designed to diagnose and treat sufferers of IBS.&nbsp; Mayo Clinic,&nbsp;Beth Israel Deaconess Medical Center Inc., a Harvard Medical School teaching hospital, University of Texas Health Science Center at Houston, Houston Methodist and the University of Michigan are participating in our clinical trials for this product.&nbsp; InFoods&#174; IBS is a unique, patented product that can allow physicians to identify specific foods (e.g., pork, milk, onions, sugar, chickpeas, etc.) for each IBS patient, that when removed from that patient&#146;s diet, may alleviate or improve their IBS symptoms and suffering.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0pt 0in; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:0.5in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 12pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:0.5in'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>Due to the global 2019 SARS-CoV-2 novel coronavirus (&#147;COVID-19&#148;) pandemic, in March 2020 we began redirecting and focusing a majority of our resources to develop, test, validate, seek regulatory approval for, and sell diagnostic products that indicate if a person has been infected by COVID-19. These diagnostic tests use a patient&#146;s blood sample to detect if the patient has certain antibodies to COVID-19 that were created as part of their body&#146;s immune response to a COVID-19 infection, even if the infection was asymptomatic. We are currently marketing and selling outside of the U.S. a disposable rapid finger-prick blood test, which detects COVID-19 IgG/IgM antibodies within 10 minutes.&nbsp; Following fiscal 2020 year-end, we submitted to the FDA an application under an Emergency Use Authorization (&#147;EUA&#148;) to sell in the U.S.&nbsp;a lab-scale, high throughput ELISA COVID-19 antibody test kit that would be sold to labs and hospitals to perform COVID-19 antibody testing. We anticipate selling this test kit outside of the U.S. under a CE Mark (European Conformity)</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Courier New"; COLOR:black'>. </font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>We are also </font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>developing and validating a COVID-19 antigen test that uses nasal (via a nasal swab) or saliva human samples to detect if the COVID-19 antigen is present in a person&#146;s nasal and oral fluids, indicating that the person has been infected with the COVID-19 virus, and may still be actively infected and infectious to others.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%'>Corporate Information</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 12pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:0.5in'><a name=GLHDR><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>We were originally incorporated in Delaware in September 1971 as Nuclear Medical Systems, Inc. We also have two wholly owned subsidiaries, Biomerica de Mexico, and BioEurope GmbH, which acts as a distributor of Biomerica products in certain markets. Our principal executive offices are located at 17571 Von Karman Avenue, Irvine, California 92614, and our telephone number is (949) 645-2111. Our corporate website address is www.biomerica.com. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only.</font></a><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'><br clear=all style=PAGE-BREAK-BEFORE:always></font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 12pt; TEXT-AUTOSPACE:ideograph-numeric' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>S-3</font></p></DIV><DIV style="PAGE-BREAK-BEFORE: always"></DIV> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; TEXT-ALIGN:center; MARGIN:10pt 0in 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Courier New"; LINE-HEIGHT:120%' lang=EN-IN> </font></div> <DIV style= 'border-style: solid;'><div><div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>The Offering</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; PAGE-BREAK-AFTER:avoid; MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:'><i></i>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; PAGE-BREAK-AFTER:avoid; MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:'><i><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>The following summary contains basic information about our common stock and the offering and is not intended to be complete. It does not contain all of the information that may be important to you. For a more complete understanding of our common stock, you should read the section entitled &#147;Description of Capital Stock.&#148;</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <div align=center> <table width=672 bordercolor=transparent style="WIDTH:503.7pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:13.35pt> <td width=343 style="HEIGHT:13.35pt; WIDTH:257.35pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>Issuer</font></b></p></td> <td width=328 style="HEIGHT:13.35pt; WIDTH:246.35pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>Biomerica, Inc.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:23.5pt> <td width=343 style="HEIGHT:23.5pt; WIDTH:257.35pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>Common stock offered</font></b></p></td> <td width=328 style="HEIGHT:23.5pt; WIDTH:246.35pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>Shares of our common stock having an aggregate offering price of up to $15,000,000.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:49pt> <td width=343 style="HEIGHT:49pt; WIDTH:257.35pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>Manner of offering</font></b></p></td> <td width=328 style="HEIGHT:49pt; WIDTH:246.35pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>&#147;At the market offering&#148; that may be made from time to time through our sales agent, B. Riley Securities. &nbsp;See &#147;Plan of Distribution&#148; beginning on page S-13 of this prospectus.</font></p></td></tr> <tr style=HEIGHT:44.55pt> <td width=343 style="HEIGHT:44.55pt; WIDTH:257.35pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>Common stock to be outstanding after this offering</font></b><sup><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>(1)</font></sup></p></td> <td width=328 style="HEIGHT:44.55pt; WIDTH:246.35pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>Up to 2,435,064 shares, assuming sales price at a price of $6.16 per share, which was the closing price of our common stock on the NASDAQ on January 20, 2021. The actual number of shares issued will vary depending on the sales price under this offering.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:44.55pt> <td width=343 style="HEIGHT:44.55pt; WIDTH:257.35pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>Risk Factors</font></b></p></td> <td width=328 style="HEIGHT:44.55pt; WIDTH:246.35pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>Your investment in our common stock involves substantial risks. You should read carefully the &#147;Risk Factors&#148; included and incorporated by reference in this prospectus, including the risk factors incorporated by reference from our filings with the SEC.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:13.35pt> <td width=343 style="HEIGHT:13.35pt; WIDTH:257.35pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>NASDAQ symbol</font></b></p></td> <td width=328 style="HEIGHT:13.35pt; WIDTH:246.35pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>BMRA</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p></td></tr> <tr style=HEIGHT:84.65pt> <td width=343 style="HEIGHT:84.65pt; WIDTH:257.35pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>Use of Proceeds</font></b></p></td> <td width=328 style="HEIGHT:84.65pt; WIDTH:246.35pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>We intend to use the net proceeds from this offering, if any, for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs. See &#147;Use of Proceeds&#148; beginning on page S-7 of this prospectus.</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric'><sup></sup>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric'><sup><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></sup><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>The common stock outstanding after the offering is based on approximately 11,770,089 shares of our common stock outstanding as of November 30, 2020 and the sale of 2,435,064 shares of our common stock at an assumed offering price of $6.16 per share, the last reported sale price of our common stock on the NASDAQ on January 20, 2021, and excludes the following: </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; MARGIN:0in 0in 0pt 0.75in; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:-0.25in'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>&#149; <font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>10,000 shares of our common stock issued upon the exercise of stock options in December, 2020;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; MARGIN:0in 0in 0pt 0.75in; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:-0.25in'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>&#149; <font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>321,429 shares of our Series A Preferred Stock </font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>outstanding as of November 30, 2020;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; MARGIN:0in 0in 0pt 0.75in; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:-0.25in'><a name=_Hlk61854534 /><a name=_Hlk61856738><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>&#149; <font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>1,908,250 shares of our common stock issuable upon the exercise of options outstanding as of November 30, 2020, having a weighted average exercise price of $3.18 per share; </font></a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; MARGIN:0in 0in 0pt 0.75in; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:-0.25in'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>&#149; <font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>236,616 shares of our common stock issuable upon the exercise of options outstanding as of November 30, 2020, having a weighted average exercise price of $6.36 per share; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; MARGIN:0in 0in 0pt 0.75in; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:-0.25in'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>&#149; <font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>35,750 shares of our common stock reserved for future issuance as of November 30, 2020 under our 2014 Stock Incentive Plan; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; MARGIN:0in 0in 0pt 0.75in; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:-0.25in'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>&#149; <font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>13,167 shares of our common stock reserved for future issuance as of November 30, 2020 under our 2017 Stock Incentive Plan; and</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; MARGIN:0in 0in 0pt 0.75in; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:-0.25in'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>&#149; <font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"'>604,000 shares of our common stock reserved for future issuance as of November 30, 2020 under our 2020 Stock Incentive Plan.</font></p></div></div> <div><p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%'>S-4</font></p></div></div><div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:10pt 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; LINE-HEIGHT:120%'> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div></DIV><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' color=#0066cc lang=EN-US><a href=#TOC> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' color=#0066cc lang=EN-US></a><a href=#TOC>Table of Contents</a><a href=#TOC></font></p></a></font></font> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US><a name=RF>RISK FACTORS</a></font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US><br><i>Before making an investment decision, you should carefully consider the risks described below and discussed in the section titled &#147;Risk Factors&#148; in our most recent Annual Report on Form 10-K, as well as the risks, uncertainties and additional information set forth in our SEC reports on Forms 10-K, 10-Q and 8-K and in other documents incorporated by reference in this prospectus. We expect to update these Risk Factors from time to time in the periodic and current reports that we file with the SEC after the date of this prospectus. These updated Risk Factors will be incorporated by reference in this prospectus.</i></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'><i></i>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'><i><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>Our business, financial condition or results of operations could be materially adversely affected by any of these risks. The trading price of our common stock could decline due to any of these risks, and you may lose all or part of your investment. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business, financial condition, results of operations and prospects. Certain statements below are forward-looking statements. See the information included under the heading &#147;Note Regarding Forward-Looking Statements.&#148;</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>Risks Related to This Offering</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'><b><i></i></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'><b><i><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>You may experience immediate and substantial dilution</font></i></b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>The offering price per share in this offering may exceed the net tangible book value per share of our common stock. Assuming that an aggregate of 2,435,064 shares of our common stock are sold at a price of $6.16 per share pursuant to this prospectus which was the last reported sale price of our common stock on the NASDAQ on January 20, 2021, for aggregate gross proceeds of $14,495,000 after deducting commissions and estimated aggregate offering expenses payable by us, you would experience immediate dilution of $4.37 per share, representing a difference between our as adjusted net tangible book value per share as of November 30, 2020 after giving effect to this offering and the assumed offering price. The exercise of outstanding stock options and warrants may result in further dilution of your investment. See the section entitled &#147;Dilution&#148; on page S-8 of this prospectus for a more detailed illustration of the dilution you would incur if you participate in this offering.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'><b><i></i></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'><b><i><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>Management will have broad discretion as to the use of the proceeds from this offering and may not use the proceeds effectively</font></i></b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>Because we have not designated the amount of net proceeds from this offering to be used for any particular purpose, our management will have broad discretion as to the application of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of the offering. Our management may use the net proceeds for corporate purposes that may not improve our financial condition or market value.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'><b><i></i></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'><b><i><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>Future sales of substantial amounts of our common stock, or the possibility that such sales could occur, could adversely affect the market price of our common stock</font></i></b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>We may issue up to $15,000,000 of common stock from time to time in this offering. The issuance from time to time of shares in this offering, as well as our ability to issue such shares in this offering, could have the effect of depressing the market price or increasing the market price volatility of our common stock. See &#147;Plan of Distribution&#148; on page S-13 of this prospectus for more information about the possible adverse effects of our sales under the sales agreement.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'><b><i></i></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'><b><i><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>It is not possible to predict the actual number of shares we will sell under the At Market Issuance Sales Agreement, or the gross proceeds resulting from those sales.</font></i></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:41pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:41pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>Subject to certain limitations in the At Market Issuance Sales Agreement and compliance with applicable law, we have the discretion to deliver a placement notice to the sales agent at any time throughout the term of the At Market Issuance Sales Agreement. The number of shares that are sold through the sales agent after delivering a placement notice will fluctuate based on a number of factors, including the market price of the common stock during the sales period, the limits we set with the sales agent in any applicable placement notice, and the demand for our common stock during the sales period.&nbsp;&nbsp;Because the price per share of each share sold will fluctuate during the sales period, it is not currently possible to predict the number of shares that will be sold or the gross proceeds to be raised in connection with those sales.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'><b><i></i></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'><b><i><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>The common stock offered hereby will be sold in &#147;at the market offerings,&#148; and investors who buy shares at different times will likely pay different prices.</font></i></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:41pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:41pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>Investors who purchase shares in this offering at different times will likely pay different prices, and so may experience different levels of dilution and different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold in this offering. In addition, there is no minimum or maximum sales price for shares to be sold in this offering. Investors may experience a decline in the value of the shares they purchase in this offering as a result of sales made at prices lower than the prices they paid.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>S-5</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; LINE-HEIGHT:120%'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' color=#0066cc lang=EN-US><a href=#TOC> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' color=#0066cc lang=EN-US></a><a href=#TOC>Table of Contents</a><a href=#TOC></font></p></a></font> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'>&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US><a name=NRFLS>NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>This prospectus and the documents incorporated by reference into this prospectus contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the success, safety and efficacy of our products, product approvals, product sales, revenues, development timelines, product acquisitions, liquidity and capital resources and trends, and other statements containing forward-looking words, such as, &#147;believes,&#148; &#147;may,&#148; &#147;could,&#148; &#147;would,&#148; &#147;will,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;estimates,&#148; &#147;anticipates,&#148; &#147;plans,&#148; &#147;seeks,&#148; or &#147;continues&#148; or the negative thereof or variation thereon or similar terminology (although not all forward-looking statements contain these words). Such forward-looking statements are based on the beliefs of our management as well as assumptions made by and information currently available to our management. Readers should not put undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified; therefore, our actual results may differ materially from those described in any forward-looking statements. The risks and uncertainties include those noted in our SEC filings or any applicable prospectus supplement.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>We urge you to consider these factors carefully in evaluating the forward-looking statements contained in this prospectus and any prospectus supplement. All subsequent written or oral forward-looking statements attributable to our company or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. The forward-looking statements included in this prospectus are made only as of the date of this prospectus. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent that we are required to do so by law.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>S-6</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; LINE-HEIGHT:120%'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; PAGE-BREAK-BEFORE:none; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><br>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US><a name=UOP>USE OF PROCEEDS</a></font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>The amount of proceeds from this offering will depend upon the number of shares of our common stock sold and the market price at which they are sold. There can be no assurance that we will be able to sell any shares under or fully utilize the sales agreement with B. Riley Securities.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>We intend to use the net proceeds from this offering, if any, for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs. We may temporarily invest the net proceeds in short-term, interest-bearing instruments or other investment-grade securities. We have not determined the amount of net proceeds to be used specifically for such purposes. As a result, management will retain broad discretion over the allocation of net proceeds.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; PAGE-BREAK-BEFORE:none; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>S-7</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; LINE-HEIGHT:120%'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:24pt 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US><a name=Dilution>DILUTION</a></font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>If you invest in our common stock, your ownership interest will be diluted to the extent of the difference between the public offering price per share and the as-adjusted net tangible book value per share after this offering. Our net tangible book value of our common stock on November 30, 2020 was approximately $10,930,450, or approximately $0.93 per share of common stock based on 11,770,089 shares outstanding. We calculate net tangible book value per share by dividing the net tangible book value, which is tangible assets less total liabilities, by the number of outstanding shares of our common stock.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>After giving effect to the sale of our common stock pursuant to this prospectus in the aggregate amount of $15,000,000 at an assumed offering price of $6.16 per share, the last reported sale price of our common stock on the NASDAQ on January 20, 2021, and after deducting commissions and estimated aggregate offering expenses payable by us, our net tangible book value as of November 30, 2020 would have been $25,425,450, or $1.79 per share of common stock. This represents an immediate increase in the net tangible book value of $0.86 per share to our existing stockholders and an immediate dilution in net tangible book value of $4.37 per share to new investors. The following table illustrates this per share dilution:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <div align=center> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:20pt> <td width=481 style="HEIGHT:20pt; WIDTH:361pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt 10pt; TEXT-AUTOSPACE:; TEXT-INDENT:-10pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Assumed offering price per share</font></p></td> <td width=87 colspan=3 style="HEIGHT:20pt; WIDTH:65pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p></td> <td width=9 style="HEIGHT:20pt; WIDTH:7pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p></td> <td width=7 style="HEIGHT:20pt; WIDTH:5.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>$</font></p></td> <td width=73 style="HEIGHT:20pt; WIDTH:54.65pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>6.16</font></p></td> <td width=5 style="HEIGHT:20pt; WIDTH:3.85pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p></td></tr> <tr style=HEIGHT:20pt> <td width=481 style="HEIGHT:20pt; WIDTH:361pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt 10pt; TEXT-AUTOSPACE:; TEXT-INDENT:-10pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Net tangible book value per share as of November 30, 2020</font></p></td> <td width=7 style="HEIGHT:20pt; WIDTH:5.5pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>$</font></p></td> <td width=74 style="HEIGHT:20pt; WIDTH:55.65pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>0.93</font></p></td> <td width=5 style="HEIGHT:20pt; WIDTH:3.85pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p></td> <td width=9 style="HEIGHT:20pt; WIDTH:7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p></td> <td width=85 colspan=3 style="HEIGHT:20pt; WIDTH:64pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p></td></tr> <tr style=HEIGHT:20pt> <td width=481 style="HEIGHT:20pt; WIDTH:361pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt 10pt; TEXT-AUTOSPACE:; TEXT-INDENT:-10pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Increase in net tangible book value per share after this offering</font></p></td> <td width=7 style="HEIGHT:20pt; WIDTH:5.5pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>$</font></p></td> <td width=74 style="HEIGHT:20pt; WIDTH:55.65pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>0.86</font></p></td> <td width=5 style="HEIGHT:20pt; WIDTH:3.85pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p></td> <td width=9 style="HEIGHT:20pt; WIDTH:7pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p></td> <td width=85 colspan=3 style="HEIGHT:20pt; WIDTH:64pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p></td></tr> <tr style=HEIGHT:20pt> <td width=481 style="HEIGHT:20pt; WIDTH:361pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt 10pt; TEXT-AUTOSPACE:; TEXT-INDENT:-10pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>As-adjusted net tangible book value per share after this offering</font></p></td> <td width=87 colspan=3 style="HEIGHT:20pt; WIDTH:65pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p></td> <td width=9 style="HEIGHT:20pt; WIDTH:7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p></td> <td width=7 style="HEIGHT:20pt; WIDTH:5.5pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>$</font></p></td> <td width=73 style="HEIGHT:20pt; WIDTH:54.65pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>1.79</font></p></td> <td width=5 style="HEIGHT:20pt; WIDTH:3.85pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p></td></tr> <tr style=HEIGHT:14pt> <td width=481 style="HEIGHT:14pt; WIDTH:361pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p></td> <td width=87 colspan=3 style="HEIGHT:14pt; WIDTH:65pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p></td> <td width=9 style="HEIGHT:14pt; WIDTH:7pt; BACKGROUND:#cceeff; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p></td> <td width=85 colspan=3 style="BORDER-TOP:windowtext 1pt solid; HEIGHT:14pt; BORDER-RIGHT:0px; WIDTH:64pt; BACKGROUND:#cceeff; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p></td></tr> <tr style=HEIGHT:20pt> <td width=481 style="HEIGHT:20pt; WIDTH:361pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:2pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt 10pt; TEXT-AUTOSPACE:; TEXT-INDENT:-10pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Dilution per share to new investors in this offering</font></p></td> <td width=87 colspan=3 style="HEIGHT:20pt; WIDTH:65pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p></td> <td width=9 style="HEIGHT:20pt; WIDTH:7pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p></td> <td width=7 style="BORDER-TOP:0px; HEIGHT:20pt; BORDER-RIGHT:0px; WIDTH:5.5pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>$</font></p></td> <td width=73 style="BORDER-TOP:0px; HEIGHT:20pt; BORDER-RIGHT:0px; WIDTH:54.65pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; ; TEXT-ALIGN:right; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=right><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>4.37</font></p></td> <td width=5 style="BORDER-TOP:0px; HEIGHT:20pt; BORDER-RIGHT:0px; WIDTH:3.85pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>The above discussion and table are based on approximately 11,770,089 shares of our common stock outstanding as of November 30, 2020 and excludes the following:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:ideograph-numeric'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt 54pt; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:-18pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>&#149; <font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>10,000 shares of our common stock issued upon the exercise of stock options in December, 2020;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt 54pt; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:-18pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>&#149; <font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>321,429 shares of our Series A Preferred Stock </font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>outstanding as of November 30, 2020;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt 54pt; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:-18pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>&#149; <font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>1,908,250 shares of our common stock issuable upon the exercise of options outstanding as of November 30, 2020, having a weighted average exercise price of $3.18 per share; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt 54pt; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:-18pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>&#149; <font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>236,616 shares of our common stock issuable upon the exercise of options outstanding as of November 30, 2020, having a weighted average exercise price of $6.36 per share; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt 54pt; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:-18pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>&#149; <font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>35,750 shares of our common stock reserved for future issuance as of November 30, 2020 under our 2014 Stock Incentive Plan; </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt 54pt; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:-18pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>&#149; <font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>13,167 shares of our common stock reserved for future issuance as of November 30, 2020 under our 2017 Stock Incentive Plan; and</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt 54pt; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:-18pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>&#149; <font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>604,000 shares of our common stock reserved for future issuance as of November 30, 2020 under our 2020 Stock Incentive Plan.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; PAGE-BREAK-BEFORE:none; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:ideograph-numeric'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>S-8</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; LINE-HEIGHT:120%'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; PAGE-BREAK-BEFORE:none; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:ideograph-numeric'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US><a name=DP>DIVIDEND POLICY</a></font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>We do not currently anticipate declaring or paying cash dividends on our capital stock in the foreseeable future. We currently intend to retain all of our future earnings, if any, to finance the operation and expansion of our business. Any future determination relating to our dividend policy will be made at the discretion of our board of directors and will depend on a number of factors, including future earnings, capital requirements, future prospects, contractual restrictions and covenants and other factors that our board of directors may deem relevant.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>S-9</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; LINE-HEIGHT:120%'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US><a name=DOCS>DESCRIPTION OF CAPITAL STOCK</a></font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>The following is a summary of all material characteristics of our capital stock as set forth in our First Amended and Restated Certificate of Incorporation, Bylaws and our Series A Certificate of Designation, as corrected, the Certificate of Designation. The summary does not purport to be complete and is qualified in its entirety by reference to our First Amended and Restated Certificate of Incorporation, Bylaws, and Certificate of Designation, copies of which have been filed as exhibits to the registration statement of which this prospectus is a part.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric'><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Common Stock</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0.5pt 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>We may issue shares of our common stock from time to time. We are authorized to issue 25,000,000 shares of common stock, par value $0.08 per share. As of November 30, 2020, there were 11,770,089 shares of common stock issued and outstanding. The holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders. The holders of common stock are not entitled to cumulative voting rights with respect to the election of directors, and as a consequence, minority stockholders will not be able to elect directors on the basis of their votes alone. Subject to preferences that may be applicable to any shares of preferred stock issued in the future, holders of common stock are entitled to receive dividends on a pro rata basis as may be declared by our board out of funds legally available therefor. In the event of a liquidation, dissolution or winding up of our Company, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preference of any then outstanding preferred stock. Holders of common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to the common stock. All outstanding shares of common stock are, and all shares of common stock to be outstanding upon completion of this offering will be, fully paid and nonassessable.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0.35pt 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric'><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Anti-Takeover Effects of Provisions of Our First Amended and Restated Certificate of Incorporation, Bylaws and Delaware Law</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0.5pt 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>We are subject to the provisions of Section 203 of the Delaware General Corporation Law. Section 203 prohibits a publicly-held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a period of three years after the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A &#147;business combination&#148; includes mergers, asset sales and other transactions resulting in a financial benefit to the interested stockholder. Subject to certain exceptions, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or within the prior three years did own, 15% or more of the corporation&#146;s voting stock.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Our First Amended and Restated Certificate of Incorporation and Bylaws, among other things, prohibit cumulative voting in the election of directors. The First Amended and Restated Certificate of Incorporation authorizes the board of directors to issue up to 5,000,000 shares of preferred stock and to determine the rights, preferences and privileges of these shares of preferred stock without any further vote or action by the stockholders, and specifies that the authorized number of directors may be changed only by a resolution of the board of directors. Special meetings of the stockholders may be called only by the board of directors, the chairman of the board of directors or the President or Secretary. The provisions described above could have the effect of making it more difficult for a third-party to acquire a majority of our outstanding voting stock, or delay, prevent or deter a merger, acquisition or tender offer in which our stockholders could receive a premium for their shares, a proxy contest or other change in our management.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0.4pt 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric'><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Preferred Stock</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0.55pt 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Pursuant to the terms of our First Amended and Restated Certificate of Incorporation, our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue up to 5,000,000 shares of preferred stock, par value $0.08 per share, in one or more series, to establish from time to time the number of shares to be included in each series, and to fix the designation, powers, preferences and rights of the shares of each series and any of its qualifications, limitations or restrictions, in each case without further action by our stockholders. Our board of directors also can increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series then outstanding. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control or the removal of management and could adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>S-10</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; LINE-HEIGHT:120%'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric'><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Series A Preferred Stock</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0.45pt 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>On February 4, 2020, we filed a Certificate of Designations, Preferences and Rights of Series A 5% Convertible Preferred Stock with the Secretary of State of the State of Delaware, which designated 571,429 of our preferred stock as Series A Preferred Stock with the powers, preferences and rights set forth therein. As of November 30, 2020, there were 321,429 shares of Series A Preferred Stock issued and outstanding.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'><i><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Voting Rights.</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Except as otherwise provided by Delaware law, other applicable law or as provided in the Certificate of Designations, the holders of our Series A Preferred Stock are not entitled to vote on any matter submitted for a vote of holders of our common stock. The consent of the holders of at least a majority of the outstanding shares of our Series A Preferred Stock will be required to, among other matters, (i) alter, amend or change adversely any rights, preferences, or privileges of our Series A Preferred Stock, (ii) amend our First Amended and Restated Certificate of Incorporation or Bylaws in any manner that would impair or reduce the rights of our Series A Preferred Stock, or (iii) amend, alter, or repeal any provision of the Certificate of Designations.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'><i><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Dividends.</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Shares of our Series A Preferred Stock accrue annual preferred dividends at a rate of $0.175 per share, which are payable when, as and if declared by our board of directors. The holders of the outstanding shares of our Series A Preferred Stock are also entitled to receive on each share of our Series A Preferred Stock dividends prior to, or simultaneously with, any dividend declared with respect to our common stock equal to the greater of (i) the amount of dividends that have accrued on such share of our Series A Preferred Stock and (ii) the dividend payable with respect to each share of our common stock issuable upon conversion of such share of our Series A Preferred Stock.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'><i><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Liquidation Preference.</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>In the event of a liquidation, dissolution or winding up of the Company, or a Deemed Liquidation Event (as defined in the Certificate of Designation) the holders of our Series A Preferred Stock are eligible to receive the greater of (i) an amount equal to $3.50 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination, or other similar recapitalization with respect to our Series A Preferred Stock) (the &#147;Original Issue Price&#148;), plus an amount equal to accrued and unpaid dividends thereon, or (ii) such amount per share as would have been payable had all shares of our Series A Preferred Stock been converted into our common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'><i><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Conversion.</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Shares of our Series A Preferred Stock are convertible at the option of the holder at any time into shares of our common stock&nbsp;at a conversion rate determined by dividing the Original Issue Price by $3.50 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination, recapitalizations, dividends, distributions and certain issuances of common stock) (the &#147;Conversion Price&#148;). This formula initially results in a one-to-one conversion ratio. The Conversion Price is subject to customary weighted average anti-dilution adjustments in the event of certain dilutive issuances of shares of our common stock or convertible securities.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>We may require the conversion of all of the outstanding shares of our Series A Preferred Stock if the closing sale price of our common stock equals or exceeds $9.00 for a period of five (5) consecutive trading days with a minimum average trading volume of 35,000 shares per day over such period.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0.05pt 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>S-11</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; LINE-HEIGHT:120%'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0.05pt 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Notwithstanding the foregoing, prior to the receipt of all approvals, if any, of the shareholders of the Company necessary for purposes of the rules and regulations of the applicable Trading Market (as defined in the Stock Purchase Agreement), our Series A Preferred Shares shall not be converted into shares of Common Stock: (i) in the aggregate into more than 19.99% of the shares of Common Stock outstanding immediately prior to the Issuance Date, subject to appropriate adjustment in the event of a stock split, stock dividend, combination or other similar recapitalization, or (ii) by any beneficial holder (as such term is defined under Rule 13d-3 of the Exchange Act) or &#147;group&#148; (as such term is defined under Rule 13d-5 of the Exchange Act) (such beneficial holder or group, a &#147;Capped Holder&#148;), if (A) the aggregate number of shares of Common Stock issued to such Capped Holder upon such conversion and any Conversion Shares then held by the Capped Holders, plus (B) the number of shares of Common Stock underlying our Series A Preferred Shares that would be held at such time by the Capped Holders (after giving effect to such conversion), plus (C) the aggregate number of shares of Common Stock held by such Capped Holder as of immediately prior to the Issuance Date, would in the aggregate exceed more than 19.99% of the shares of Common Stock outstanding immediately prior to the Issuance Date (without regard to any limitation on conversion pursuant to this Section 5(n)), then such Capped Holder shall be entitled to convert such number of our Series A Preferred Shares as would result in the sum of clauses (A), (B) and (C) (after giving effect to such conversion) being equal to 19.99% of the shares of Common Stock outstanding immediately prior to the Issuance Date, in each case, subject to appropriate adjustment in the event of a stock split, stock dividend, combination or other similar recapitalization. Any Series A Preferred Shares which a holder has elected to convert but which, by reason of the previous sentence are not so converted, shall be treated as if the holder had not made such election to convert and such Series A Preferred Shares shall remain outstanding.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'><i><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Ranking.</font></i></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Our Series A Preferred Stock ranks senior to our common stock with respect to distributions upon any liquidation, on parity to any class or series of our capital stock hereafter created specifically ranking by its terms on parity with our Series A Preferred Stock and junior to any class or series of our capital stock hereafter created specifically ranking by its terms senior to our Series A Preferred Stock.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0.55pt 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric'><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>NASDAQ Capital Market Listing</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Our common stock is listed on the NASDAQ Capital Market and traded under the symbol &#147;BMRA.&#148; On January 20, 2021, the last reported sale price for our common stock on the NASDAQ Capital Market was $</font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>6.16</font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US> per share.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0.4pt 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric'><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Transfer Agent and Registrar</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0.55pt 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>The transfer agent and registrar for the common stock is Issuer Direct. The transfer agent and registrar&#146;s address is 1981 East 4800 So, Suite 100, Salt Lake City, Utah 84117.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; PAGE-BREAK-BEFORE:none; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>S-12</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; LINE-HEIGHT:120%'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; PAGE-BREAK-BEFORE:none; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US><a name=POD>PLAN OF DISTRIBUTION</a></font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>We have entered into an amendment dated January 22, 2021 to our sales agreement with B. Riley Securities on December 1, 2017 (together, the &#147;sales agreement&#148;), which we filed as an exhibit to our Current Report on Form 8-K on December 1, 2017 and incorporate by reference in this prospectus supplement and the accompanying prospectus.&nbsp; Under the terms of the sales agreement, we may offer and sell up to $15,000,000 of shares of our common stock under this prospectus from time to time through the sales agent. Sales of shares of our common stock, if any, under this prospectus may be made in transactions that are deemed to be &#147;at the market offerings&#148; as defined in Rule 415 under the Securities Act.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>We will pay the sales agent commissions for its services in acting as agent in the sale of our common stock at a commission rate equal to up to 3.0% of the gross sale price per share sold..&nbsp;We estimate that the total expenses for the offering, excluding compensation and reimbursements payable to the sales agent under the sales agreement, will be approximately $35,000.&nbsp; We have also agreed to reimburse the sales agent for its reasonable out-of-pocket expenses, including attorney&#146;s fees, in connection with the offering pursuant to this prospectus supplement in an amount not to exceed an aggregate of $20,000.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>Settlement for sales of common stock will occur on the second business day following the date on which any sales are made, or on some other date that is agreed upon by us and the sales agent in connection with a particular transaction, in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>In connection with the sale of the common stock on our behalf, B. Riley Securities will be deemed to be an underwriter within the meaning of the Securities Act, and its compensation as sales agent will be deemed to be underwriting commissions or discounts. B. Riley Securities may retain Colliers Securities LLC as a sub-agent in connection with this offering and may pay a portion of its compensation hereunder to such sub-agent. We have agreed to provide indemnification and contribution to B. Riley Securities against certain civil liabilities, including liabilities under the Securities Act.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>The offering pursuant to this prospectus supplement will terminate upon the earlier of (1) the issuance and sale of all shares of our common stock subject to this prospectus supplement; and (2) the termination of the sales agreement as permitted therein.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>The prospectus in electronic format may be made available on websites maintained by the sales agent.&nbsp; The sales agent and its affiliates have in the past and may in the future provide various investment banking and other financial services for us and our affiliates, for which services it may in the future receive customary fees. To the extent required by Regulation M, the sales agent will not engage in any market making activities involving our common stock while the offering is ongoing under this prospectus supplement. This summary of the material provisions of the sales agreement does not purport to be a complete statement of its terms and conditions. </font></p></div><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US><br clear=all style=PAGE-BREAK-BEFORE:none></font></b> <div style=page:WordSection5> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>S-13</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; LINE-HEIGHT:120%'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US><a name=LM>LEGAL MATTERS</a></font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>Certain legal matters will be passed upon for us by Stradling Yocca Carlson &amp; Rauth, P.C., Newport Beach, California. Certain legal matters will be passed upon for B. Riley Securities by Duane Morris LLP, New York, New York.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US><a name=Experts>EXPERTS</a></font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><a name=_MailEndCompose><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>The consolidated financial statements, and the related financial statement schedule, incorporated in this prospectus by reference from the Company&#146;s Annual Report on Form 10-K for the year ended May 31, 2020 have been audited by PFK, LLP, an independent registered public accounting firm, as stated in their reports, which are incorporated herein by reference. Such financial statements and financial statement schedule have been so incorporated in reliance upon the reports of such firm given upon their authority as experts in accounting and auditing.</font></a></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US><a name=WYCFMI>WHERE YOU CAN FIND MORE INFORMATION</a></font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>We file annual, quarterly and current reports and other information with the SEC. Our filings with the SEC are available from the SEC&#146;s internet site at http://www.sec.gov, which contains reports, proxy and information statements, and other information regarding issuers that file electronically.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>This prospectus supplement and the accompanying prospectus are part of a registration statement that we filed with the SEC.&nbsp; As permitted by SEC rules, this prospectus supplement and the accompanying prospectus form a part of the registration statement, but do not contain all of the information that is included in the registration statement. The registration statement contains more information regarding us and our securities, including certain exhibits. You can obtain a copy of the registration statement from the SEC at the address listed above or from the SEC&#146;s website.</font></p></div><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US><br clear=all style=PAGE-BREAK-BEFORE:none></font> <div style=page:WordSection6> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>S-14</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; LINE-HEIGHT:120%'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US><a name=IOCDBR>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</a></font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>This prospectus is part of a registration statement on Form S-3 filed by us with the SEC. This prospectus does not contain all of the information set forth in the registration statement, certain parts of which are omitted in accordance with the rules and regulations of the SEC. For further information about us and the securities offered by this prospectus, we refer you to the registration statement and its exhibits and schedules which may be obtained as described herein.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>The SEC allows us to &#147;incorporate by reference&#148; information into this prospectus. This means that we can disclose important information about us and our financial condition to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be part of this prospectus. This prospectus incorporates by reference the documents listed below that we have previously filed with the SEC:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt 36pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:-18pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>&#149; <font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>Our Annual Report on Form 10-K for the fiscal year ended May 31, 2020, as filed with the SEC on August 31, 2020;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt 36pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:-18pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>&#149; <font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>Our Quarterly Report on Form 10-Q for the fiscal quarter ended August 31, 2020, as filed with the SEC on October 15, 2020, and our Quarterly Report on Form 10-Q for the fiscal quarter ended November 30, 2020, as filed with the SEC on January 14, 2021;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt 36pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:-18pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>&#149; <font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>The information specifically incorporated by reference into our Annual Report on Form 10-K from our Definitive Proxy Statement on Schedule 14A, as filed with the SEC on September 25, 2020;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt 36pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:-18pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>&#149; <font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>Our Current Reports on Form 8-K, as filed with the SEC on June 2, 2020, June 17, 2020, June 29, 2020, September 2, 2020, December 11, 2020 (two reports) and January 14, 2021; and </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt 36pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric; TEXT-INDENT:-18pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>&#149; <font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>The description of our common stock set forth in the Registration Statement on Form 8-A filed with the SEC on August 23, 2016 and any other amendment or report filed for the purpose of updating such description.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt 36pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:ideograph-numeric'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>We also incorporate by reference into this prospectus all documents filed by us with the SEC pursuant to Sections 12(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of any offering of securities made by this prospectus, including all such documents we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration statement. Nothing in this prospectus shall be deemed to incorporate information furnished but not filed with the SEC (including without limitation, information furnished under Item 2.02 or Item 7.01 of Form 8-K, and any exhibits relating to such information).</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>Any statement contained in this prospectus or in a document incorporated or deemed to be incorporated by reference in this prospectus shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein or in the applicable prospectus supplement or in any other subsequently filed document which also is or is deemed to be incorporated by reference modifies or supersedes the statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>You may request a copy of the filings incorporated herein by reference, including exhibits to such documents that are specifically incorporated by reference, at no cost, by writing or calling us at the following address or telephone number:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>Biomerica, Inc.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>17571 Von Karman Ave.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>Irvine, California 92614</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>Telephone: (949) 645-2111</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>Attention: Investor Relations</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0pt; TEXT-JUSTIFY:inter-ideograph; TEXT-AUTOSPACE:; TEXT-INDENT:36pt'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>Statements contained in this prospectus as to the contents of any contract or other documents are not necessarily complete, and in each instance investors are referred to the copy of the contract or other document filed as an exhibit to the registration statement, each such statement being qualified in all respects by such reference and the exhibits and schedules thereto.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' lang=EN-US>S-15</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; LINE-HEIGHT:120%'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 10pt; LINE-HEIGHT:120%; TEXT-AUTOSPACE:'><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; LINE-HEIGHT:120%' color=#0066cc lang=EN-US><a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:'>&nbsp;</p></div><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US><br clear=all style=PAGE-BREAK-BEFORE:none></font> <div style=page:WordSection1> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0.55pt 42.8pt 0pt 41.8pt; LINE-HEIGHT:normal' align=center>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0.55pt 42.8pt 0pt 41.8pt; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:10.5pt; FONT-FAMILY:"Times New Roman","serif"'>$90,000,000</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0.05pt 42.8pt 0pt 41.8pt; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:10.5pt; FONT-FAMILY:"Times New Roman","serif"'>BIOMERICA, INC.</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:10.65pt 42.8pt 0pt 41.8pt; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:10.5pt; FONT-FAMILY:"Times New Roman","serif"'>Common Stock</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:10.65pt 178.15pt 0pt 177.1pt; LINE-HEIGHT:11.2pt; TEXT-INDENT:-0.05pt' align=center><b><font style='FONT-SIZE:10.5pt; FONT-FAMILY:"Times New Roman","serif"'>571,429 Shares of Common Stock Offered by the Selling Stockholder</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:10.15pt 11.1pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>This prospectus relates to a primary offering by us, and a secondary offering by the selling stockholder identified in this prospectus.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.35pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0.05pt 47.25pt 0pt 41.1pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>From time to time, we may offer and sell shares of our common stock with total gross proceeds of up to $90,000,000.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:8.95pt 11.2pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>This prospectus also relates to the offer and resale of up to an aggregate of 571,429 shares of our common stock held by the selling stockholder or issuable upon conversion of shares of our Series A Convertible Preferred Stock, $0.08 par value per share, or our Series A Preferred Stock, held by the selling stockholder. The selling stockholder may sell any, all or none of the securities offered by this prospectus, and we do not know when or in what amount the selling stockholder may sell its shares of common stock hereunder following the effective date of this registration statement. We will not receive any proceeds from the resale of shares of our common stock by the selling stockholder.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:9pt 11.2pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>This prospectus provides a general description of the shares of common stock that we and the selling stockholder may offer. Each time we sell shares of our common stock, we will provide the specific terms of the offering in a prospectus supplement. To the extent that the selling stockholder resells any securities, the selling stockholder may be required to provide you with a prospectus supplement containing specific information about the selling stockholder and the specific terms of the offering.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.4pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 11.2pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Any prospectus supplement that we or the selling stockholder provide to you may add, update or change information in this prospectus. You should read this prospectus and any prospectus supplement, as well as the documents incorporated by reference herein and therein, carefully before you invest in any securities.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.4pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 11.3pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>This prospectus may not be used to consummate a sale of our common stock unless accompanied by a prospectus supplement.</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.4pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 11.25pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Our common stock is traded on the NASDAQ Capital Market under the symbol &#147;BMRA.&#148; On July 17, 2020, the last reported sale price of our common stock was $10.96 per share.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.4pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 11.15pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>We may sell shares of our common stock directly to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section entitled &#147;Plan of Distribution&#148; in this prospectus. If any agents or underwriters are involved in the sale of any shares of our common stock with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts or over-allotment options will be set forth in a prospectus supplement. The price to the public of such shares and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 11.15pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal'>&nbsp;</p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:6.5pt; FONT-FAMILY:"Times New Roman","serif"'><br clear=all></font>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:4.6pt 10.55pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal'><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>INVESTING IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES DESCRIBED UNDER THE HEADING &#147;RISK FACTORS&#148; BEGINNING ON PAGE 5 OF THIS PROSPECTUS, CONTAINED IN ANY APPLICABLE PROSPECTUS SUPPLEMENT AND ANY RELATED FREE WRITING PROSPECTUS, AND UNDER SIMILAR HEADINGS IN THE OTHER DOCUMENTS THAT ARE INCORPORATED BY REFERENCE INTO THIS PROSPECTUS.</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:8.95pt 11.35pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal'><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-FAMILY:"Times New Roman","serif"'><br clear=all></font>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>The date of this prospectus is</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'> September 30</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>, 2020.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center>&nbsp;</p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:4.65pt 42.8pt 0pt 41.8pt; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'><a name=TOC>TABLE OF CONTENTS</a></font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:4.65pt 42.8pt 0pt 41.8pt; LINE-HEIGHT:normal' align=center>&nbsp;</p> <div align=center> <table width=667 bordercolor=transparent style="WIDTH:500pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15.45pt> <td width=566 style="HEIGHT:15.45pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top /> <td width=46 style="HEIGHT:15.45pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>Page</font></b></p></td></tr> <tr style=HEIGHT:12.4pt> <td width=566 style="HEIGHT:12.4pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=top> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=46 style="HEIGHT:12.4pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15.45pt> <td width=566 style="HEIGHT:15.45pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'><a href=#ATP2>ABOUT THIS PROSPECTUS</a></font></p></td> <td width=46 style="HEIGHT:15.45pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>1</font></p></td></tr> <tr style=HEIGHT:12.4pt> <td width=566 style="HEIGHT:12.4pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=46 style="HEIGHT:12.4pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:12.4pt> <td width=566 style="HEIGHT:12.4pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'><a href=#SNRFLI2>SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION</a></font></p></td> <td width=46 style="HEIGHT:12.4pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>2</font></p></td></tr> <tr style=HEIGHT:12.4pt> <td width=566 style="HEIGHT:12.4pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=46 style="HEIGHT:12.4pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15.45pt> <td width=566 style="HEIGHT:15.45pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'><a href=#ATC2>ABOUT THE COMPANY</a></font></p></td> <td width=46 style="HEIGHT:15.45pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>3</font></p></td></tr> <tr style=HEIGHT:12.4pt> <td width=566 style="HEIGHT:12.4pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=46 style="HEIGHT:12.4pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15.45pt> <td width=566 style="HEIGHT:15.45pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'><a href=#RF2>RISK FACTORS</a></font></p></td> <td width=46 style="HEIGHT:15.45pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>5</font></p></td></tr> <tr style=HEIGHT:12.4pt> <td width=566 style="HEIGHT:12.4pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=46 style="HEIGHT:12.4pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15.45pt> <td width=566 style="HEIGHT:15.45pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'><a href=#UOP2>USE OF PROCEEDS</a></font></p></td> <td width=46 style="HEIGHT:15.45pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>6</font></p></td></tr> <tr style=HEIGHT:12.4pt> <td width=566 style="HEIGHT:12.4pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=46 style="HEIGHT:12.4pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15.45pt> <td width=566 style="HEIGHT:15.45pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'><a href=#DOCS2>DESCRIPTION OF CAPITAL STOCK</a></font></p></td> <td width=46 style="HEIGHT:15.45pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>7</font></p></td></tr> <tr style=HEIGHT:12.4pt> <td width=566 style="HEIGHT:12.4pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=46 style="HEIGHT:12.4pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15.45pt> <td width=566 style="HEIGHT:15.45pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'><a href=#SS2>SELLING STOCKHOLDERS</a></font></p></td> <td width=46 style="HEIGHT:15.45pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>10</font></p></td></tr> <tr style=HEIGHT:12.4pt> <td width=566 style="HEIGHT:12.4pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=46 style="HEIGHT:12.4pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15.45pt> <td width=566 style="HEIGHT:15.45pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'><a href=#POD2>PLAN OF DISTRIBUTION</a></font></p></td> <td width=46 style="HEIGHT:15.45pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>12</font></p></td></tr> <tr style=HEIGHT:12.4pt> <td width=566 style="HEIGHT:12.4pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=46 style="HEIGHT:12.4pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15.45pt> <td width=566 style="HEIGHT:15.45pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'><a href=#LM2>LEGAL MATTERS</a></font></p></td> <td width=46 style="HEIGHT:15.45pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>14</font></p></td></tr> <tr style=HEIGHT:12.4pt> <td width=566 style="HEIGHT:12.4pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=46 style="HEIGHT:12.4pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15.45pt> <td width=566 style="HEIGHT:15.45pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'><a href=#Experts2>EXPERTS</a></font></p></td> <td width=46 style="HEIGHT:15.45pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>14</font></p></td></tr> <tr style=HEIGHT:12.4pt> <td width=566 style="HEIGHT:12.4pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=46 style="HEIGHT:12.4pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:15.45pt> <td width=566 style="HEIGHT:15.45pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'><a href=#IOCDBR2>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</a></font></p></td> <td width=46 style="HEIGHT:15.45pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>15</font></p></td></tr> <tr style=HEIGHT:12.4pt> <td width=566 style="HEIGHT:12.4pt; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p></td> <td width=46 style="HEIGHT:12.4pt; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right>&nbsp;</p></td></tr> <tr style=HEIGHT:0.25in> <td width=566 style="HEIGHT:0.25in; WIDTH:424.85pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'><a href=#WYCFMI2>WHERE YOU CAN FIND MORE INFORMATION</a></font></p></td> <td width=46 style="HEIGHT:0.25in; WIDTH:34.15pt; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>16</font></p></td></tr></table></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:16.15pt 0.95pt 0pt 0in; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>0</font></p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;<a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:4.65pt 42.75pt 0pt 41.8pt; LINE-HEIGHT:normal' align=center><a name=ATP2><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>ABOUT THIS PROSPECTUS</font></b></a></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 11.25pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.1pt'>This prospectus&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>is&nbsp;<font style=LETTER-SPACING:0.1pt>part&nbsp;</font>of a&nbsp;<font style=LETTER-SPACING:0.1pt>registration&nbsp;</font><font style=LETTER-SPACING:0.15pt>statement&nbsp;</font><font style=LETTER-SPACING:0.1pt>that&nbsp;</font>we&nbsp;<font style=LETTER-SPACING:0.1pt>filed with&nbsp;</font>the&nbsp;<font style=LETTER-SPACING:0.1pt>Securities and Exchange Commission (the &#147;SEC&#148;)&nbsp;</font><font style=LETTER-SPACING:0.15pt>using&nbsp;</font>a&nbsp;<font style=LETTER-SPACING:0.15pt>&#147;shelf&#148; registration process. Under this shelf registration process,&nbsp;</font>we&nbsp;<font style=LETTER-SPACING:0.15pt>may sell shares&nbsp;</font>of&nbsp;<font style=LETTER-SPACING:0.1pt>our&nbsp;</font><font style=LETTER-SPACING:0.15pt>common stock&nbsp;</font>in&nbsp;<font style=LETTER-SPACING:0.1pt>one&nbsp;</font>or&nbsp;<font style=LETTER-SPACING:0.2pt>more&nbsp;</font>offerings up to a total aggregate offering price of $90,000,000. This prospectus also relates to the offer and resale of up to an aggregate of 571,429 shares of our common stock held by the selling stockholder or issuable upon conversion of shares of our Series A Preferred Stock, held by the selling stockholder. The selling stockholder is identified in this prospectus under the heading &#147;Selling Stockholders&#148;. This prospectus provides you with a general description of our common stock that we and the selling stockholder may offer.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.35pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 42.7pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>All references to &#147;Company&#148; &#147;we,&#148; &#147;our&#148; or &#147;us&#148; refer solely to Biomerica, Inc.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:8.9pt 11pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Each time we sell shares of our common stock, we will provide the specific terms of the offering in a prospectus supplement.&nbsp; To the extent that the selling stockholder resells any shares of our common stock, the selling stockholder may be required to provide you with a prospectus supplement containing specific information about the selling stockholder and the specific terms of the offering. Any prospectus supplement that we or the selling stockholder provide to you may add, update or change information in this prospectus. To the extent there is a conflict between the information contained in this prospectus and any accompanying prospectus supplement,&nbsp;<font style=LETTER-SPACING:0.1pt>you&nbsp;</font>should rely on the information in the prospectus supplement. This prospectus, together with any accompanying prospectus supplement, includes all material information relating to an offering pursuant to this&nbsp;<font style=LETTER-SPACING:0.1pt>registration statement.&nbsp;</font>You should read&nbsp;<font style=LETTER-SPACING:0.1pt>this prospectus,&nbsp;</font><font style=LETTER-SPACING:0.15pt>any&nbsp;</font><font style=LETTER-SPACING:0.2pt>applicable prospectus supplement&nbsp;</font><font style=LETTER-SPACING:0.15pt>and any&nbsp;</font><font style=LETTER-SPACING:0.2pt>related&nbsp;</font><font style=LETTER-SPACING:0.15pt>free&nbsp;</font><font style=LETTER-SPACING:0.2pt>writing prospectus, together&nbsp;</font><font style=LETTER-SPACING:0.15pt>with the&nbsp;</font><font style=LETTER-SPACING:0.2pt>information incorporated herein&nbsp;</font><font style=LETTER-SPACING:0.25pt>by&nbsp;</font>reference as described under the heading &#147;Incorporation of Certain Information by Reference,&#148; before investing in our common stock.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:9pt 11.25pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Neither we, nor any agent, underwriter, dealer, salesperson or other person has authorized any person to give any information&nbsp; or to make any representations other than those contained or incorporated by reference in this prospectus, any accompanying prospectus supplement or any related free writing prospectus in connection with the offer made by this prospectus, any accompanying prospectus&nbsp;<font style=LETTER-SPACING:0.25pt>supplement&nbsp;</font><font style=LETTER-SPACING:0.15pt>or&nbsp;</font><font style=LETTER-SPACING:0.2pt>any&nbsp;</font><font style=LETTER-SPACING:0.25pt>related&nbsp;</font><font style=LETTER-SPACING:0.2pt>free&nbsp;</font><font style=LETTER-SPACING:0.25pt>writing prospectus.&nbsp;</font><font style=LETTER-SPACING:0.2pt>You must not rely upon any&nbsp;</font><font style=LETTER-SPACING:0.25pt>information&nbsp;</font><font style=LETTER-SPACING:0.15pt>or&nbsp;</font><font style=LETTER-SPACING:0.25pt>representation&nbsp;</font><font style=LETTER-SPACING:0.2pt>not&nbsp;</font><font style=LETTER-SPACING:0.25pt>contained&nbsp;</font><font style=LETTER-SPACING:0.15pt>or&nbsp;</font>incorporated by reference in this prospectus or any accompanying prospectus supplement as if we had authorized it.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:8.95pt 11.3pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>This prospectus, any accompanying prospectus supplement or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor does this prospectus, any accompanying prospectus supplement or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.35pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 11.2pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>You should not assume that the information contained in this prospectus, any accompanying prospectus supplement or any related free writing prospectus is correct on any date after their respective dates or that any information we have incorporated by reference is correct on any date after the date of the document incorporated by reference, even though this prospectus, any accompanying prospectus supplement or any related free writing prospectus may be delivered or securities may be sold on a later date.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:8.9pt 11.25pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Investing in our securities involves a high degree of risk. You should carefully consider the section entitled &#147;Risk Factors&#148; in this prospectus, any accompanying prospectus supplement and any related free writing prospectus before you invest in our securities.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:8.9pt 10.95pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>You should also carefully read the additional information described in the sections entitled &#147;Incorporation of Certain Documents by Reference&#148; and &#147;Where You Can Find More Information&#148; before you invest in our securities.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:8.9pt 10.95pt 0pt 0in; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>1</font></p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;<a href=#TOC><font style=FONT-SIZE:10pt face="Times New Roman">Table of Contents</font></a></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-FAMILY:"Times New Roman","serif"'><br clear=all></font>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:4.6pt 1.8pt 0pt; LINE-HEIGHT:normal' align=center><a name=SNRFLI2><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION</font></b></a></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.45pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.1pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>This prospectus, any accompanying prospectus supplement, and the documents we incorporate by reference in this prospectus and any accompanying prospectus supplement, contains forward-looking statements within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties. These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements. We have attempted to identify forward-looking statements by using words such as &#147;may,&#148; &#147;believe,&#148; &#147;will,&#148; &#147;could,&#148; &#147;project,&#148; &#147;anticipate,&#148; &#147;expect,&#148; &#147;estimate,&#148; &#147;should,&#148; &#147;continue,&#148; &#147;potential,&#148; &#147;plan,&#148; &#147;forecasts,&#148; &#147;goal,&#148; &#147;seek,&#148; &#147;intend,&#148; other forms of these words or similar words or expressions or the negative thereof.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.5pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0.05pt 10.1pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>We have based our forward-looking statements on our expectations and projections about trends affecting our business and industry and other future events. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Forward-looking statements are subject to substantial risks and uncertainties that could cause our future business, financial condition, results of operations or performance, to differ materially from our historical results or those expressed or implied in any forward-looking statement. Some of the risks and uncertainties that may cause actual results to differ from those expressed or implied in the forward-looking statements are described in the section entitled &#147;Risk Factors&#148; in this prospectus and in any accompanying prospectus supplement, as well as in our other filings with the SEC. In addition, actual results may differ as a result of additional risks and uncertainties of which we are currently unaware or which we do not currently view as material to our business. For these reasons, investors are cautioned not to place undue reliance on any forward-looking statements.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.5pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.05pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>You should read this prospectus in its entirety, together with any accompanying prospectus supplement, the documents that we file as exhibits to the registration statement of which this prospectus is a part, and the documents that we incorporate by reference into this prospectus and any accompanying prospectus supplement, with the understanding that our future results may be materially different from what we currently expect. The forward-looking statements we make speak only as of the date on which they are made. We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations, except as required by applicable law or the rules of the NASDAQ Stock Market. If we do update or correct any forward-looking statements, investors should not conclude that we will make additional updates or corrections.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 42.7pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>We qualify all of our forward-looking statements by these cautionary statements.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:8.9pt 10.95pt 0pt 0in; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>2</font></p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;<a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:4.6pt 1.8pt 0pt 1.75pt; LINE-HEIGHT:normal' align=center><a name=ATC2><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>ABOUT THE COMPANY</font></b></a></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.45pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 1.5pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:16.2pt'><i><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>The following is a summary of what we believe to be the most important aspects of our business. Please read the additional information in the sections entitled &#147;Incorporation of Certain Documents by Reference&#148; and &#147;Where You Can Find More Information.&#148;</font></i></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.5pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0.05pt 1.8pt 0pt; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Our Company</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.15pt'>We are&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>a&nbsp;<font style=LETTER-SPACING:0.2pt>global medical device company&nbsp;</font><font style=LETTER-SPACING:0.15pt>that&nbsp;</font><font style=LETTER-SPACING:0.2pt>develops, patents, manufactures and/or markets advanced diagnostic&nbsp;</font><font style=LETTER-SPACING:0.25pt>and&nbsp;</font><font style=LETTER-SPACING:0.15pt>therapeutic&nbsp;</font><font style=LETTER-SPACING:0.1pt>products used&nbsp;</font>at&nbsp;<font style=LETTER-SPACING:0.1pt>the point-of-care (in home&nbsp;</font>and in&nbsp;<font style=LETTER-SPACING:0.1pt>physicians' offices)&nbsp;</font>and in&nbsp;<font style=LETTER-SPACING:0.1pt>hospital/clinical laboratories&nbsp;</font>for&nbsp;<font style=LETTER-SPACING:0.15pt>detection&nbsp;</font><font style=LETTER-SPACING:0.1pt>and/or treatment&nbsp;</font>of&nbsp;<font style=LETTER-SPACING:0.1pt>medical conditions and diseases.&nbsp;</font>The&nbsp;<font style=LETTER-SPACING:0.1pt>Company's products&nbsp;</font>are&nbsp;<font style=LETTER-SPACING:0.1pt>designed&nbsp;</font>to&nbsp;<font style=LETTER-SPACING:0.1pt>enhance&nbsp;</font>the&nbsp;<font style=LETTER-SPACING:0.1pt>health and well-being&nbsp;</font><font style=LETTER-SPACING:0.15pt>of&nbsp;</font>people, while reducing total healthcare costs. Our diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.4pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.05pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.1pt'>Our&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.15pt'>primarily focus&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>is on&nbsp;<font style=LETTER-SPACING:0.2pt>gastrointestinal,&nbsp;</font><font style=LETTER-SPACING:0.15pt>food&nbsp;</font><font style=LETTER-SPACING:0.2pt>intolerance&nbsp;</font><font style=LETTER-SPACING:0.1pt>and&nbsp;</font><font style=LETTER-SPACING:0.2pt>inflammatory diseases&nbsp;</font><font style=LETTER-SPACING:0.15pt>where the&nbsp;</font><font style=LETTER-SPACING:0.2pt>Company&nbsp;</font><font style=LETTER-SPACING:0.15pt>has&nbsp;</font><font style=LETTER-SPACING:0.25pt>multiple&nbsp;</font>diagnostic and therapeutic products in development. In response to the COVID-19 pandemic, we have lunched various serology tests&nbsp; that look for the presence of antibodies to the novel Coronavirus (SARS-CoV-2). The antibodies detected by serology tests can indicate&nbsp;<font style=LETTER-SPACING:0.15pt>that&nbsp;</font>a&nbsp;<font style=LETTER-SPACING:0.15pt>person&nbsp;</font><font style=LETTER-SPACING:0.1pt>has had&nbsp;</font>an&nbsp;<font style=LETTER-SPACING:0.15pt>immune response&nbsp;</font>to&nbsp;<font style=LETTER-SPACING:0.1pt>the&nbsp;</font><font style=LETTER-SPACING:0.15pt>SARS-CoV-2, whether symptoms developed&nbsp;</font><font style=LETTER-SPACING:0.1pt>from&nbsp;</font><font style=LETTER-SPACING:0.15pt>infection&nbsp;</font>or&nbsp;<font style=LETTER-SPACING:0.1pt>the&nbsp;</font><font style=LETTER-SPACING:0.15pt>infection&nbsp;</font><font style=LETTER-SPACING:0.2pt>was&nbsp;</font>asymptomatic.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.4pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.2pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Our InFoods&#174; IBS product which is currently in clinical trials in the US, is designed to allow physicians to identify patient specific foods (e.g. eggs, broccoli, wheat, potatoes, corn, etc.), that when removed from the diet, may alleviate or improve an individual's IBS symptoms including, but not limited to, constipation, diarrhea, bloating, pain and indigestion. The InFoods IBS product is a patented diagnostic-guided therapy and is being tested to allow for a patient specific, guided dietary regimen to improve Irritable Bowel Syndrome (IBS) outcomes. An estimated 45 million people in America currently suffer from IBS making it a leading cause for patient doctor visits.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.4pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.2pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>We primarily focus on products for gastrointestinal diseases, food intolerances, diabetes and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Our products are CE marked and/or sold for diagnostic or treatment use around the world where they are registered by each country&#146;s regulatory agency.&nbsp;&nbsp;&nbsp;&nbsp; In addition, some products are cleared for sale in the</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 10.3pt; LINE-HEIGHT:10.3pt'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>U.S. by the U.S. Food and Drug Administration, or FDA.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.05pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>We maintain our headquarters in Irvine, California where we house administration, product development, sales and marketing, customer services and some manufacturing operations. A part of our manufacturing and assembly operations is located in Mexicali, Mexico, in order to reduce the cost of manufacturing and compete more effectively worldwide. We have established wholly owned subsidiaries in both Mexico and Germany. We expend considerable funds in research and development of certain new products that diagnose and, in certain cases, are designed to be used as a therapy for several major medical diseases. These products are both internally developed and licensed from others. We utilize experienced technical personnel to improve existing products, develop new products and evaluate and license or purchase technologies owned by third parties that could be implemented into products we sell. We are currently pursuing the development of multiple tests for the gastrointestinal market, and other disease states that pertain to a patient&#146;s food intolerance, as well as several diagnostic tests that identify persons that have been infected with the COVID-19 virus.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 1.8pt 0pt; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Corporate Information</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.35pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>We were originally incorporated in Delaware in September 1971 as Nuclear Medical Systems, Inc. We also have two wholly owned subsidiaries, Biomerica de Mexico, and BioEurope GmbH, which acts as a distributor of Biomerica products in certain markets. Our principal executive offices are located at 17571 Von Karman Avenue, Irvine, California 92614, and our telephone number is (949) 645-2111. Our corporate website address is&nbsp;www.biomerica.com.&nbsp;Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:8.9pt 10.95pt 0pt 0in; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>3</font></p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;<a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.15pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:4.6pt 1.8pt 0pt; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Implications of Being a Smaller Reporting Company</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 13.05pt 0pt 10.3pt; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>We are a &#147;smaller reporting company&#148; as defined in the Securities Exchange Act of 1934, or the Exchange Act, and have elected to take advantage of certain of the scaled disclosures available to smaller reporting companies.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 13.05pt 0pt 0in; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:8.9pt 10.95pt 0pt 0in; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>4</font></p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;<a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:4.65pt 1.8pt 0pt; LINE-HEIGHT:normal' align=center><a name=RF2><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>RISK FACTORS</font></b></a></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.3pt 0pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks described in (i) the sections entitled &#147;Risk Factors&#148; in our most recent Annual Report on Form 10-K and subsequent quarterly, annual and other reports, each as filed with the SEC, which are incorporated by reference in this prospectus in their entirety and (ii) any amendment or updates to our risk factors reflected in subsequent filings with the SEC, including in any applicable prospectus supplement or related free writing prospectus. For more information, see the sections entitled &#147;Incorporation of Certain Documents by Reference&#148; and &#147;Where You Can Find More Information.&#148; Our business, financial condition or results of operations could be materially adversely affected by any of these risks. In addition, the trading price of our securities could decline due to any of these risks, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business, financial condition or results of operations.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.2pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>This prospectus and the documents we incorporate by reference in this prospectus contain forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks described in this prospectus and in the documents incorporated by reference in this prospectus. For more information, see &#147;Special Note Regarding Forward-Looking Information.&#148;</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:8.9pt 10.95pt 0pt 0in; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>5</font></p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;<a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:4.6pt 1.8pt 0pt 1.75pt; LINE-HEIGHT:normal' align=center><a name=UOP2><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>USE OF PROCEEDS</font></b></a></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.45pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.2pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.1pt'>We&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.15pt'>will retain broad discretion over&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.1pt'>the use&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>of&nbsp;<font style=LETTER-SPACING:0.1pt>the net&nbsp;</font><font style=LETTER-SPACING:0.15pt>proceeds&nbsp;</font><font style=LETTER-SPACING:0.1pt>from&nbsp;</font>the&nbsp;<font style=LETTER-SPACING:0.15pt>sale&nbsp;</font>of&nbsp;<font style=LETTER-SPACING:0.1pt>our common stock&nbsp;</font><font style=LETTER-SPACING:0.15pt>offered&nbsp;</font>by us&nbsp;<font style=LETTER-SPACING:0.15pt>hereby.&nbsp;</font>Except as described in any prospectus supplement or any related free writing prospectus that we may authorize to be provided to you,&nbsp; we currently intend to use the net proceeds from the sale of our common stock offered hereby for working capital and general corporate&nbsp;<font style=LETTER-SPACING:0.1pt>purposes, which&nbsp;</font>may&nbsp;<font style=LETTER-SPACING:0.1pt>include capital expenditures,&nbsp;</font>debt&nbsp;<font style=LETTER-SPACING:0.1pt>repayment, research&nbsp;</font>and&nbsp;<font style=LETTER-SPACING:0.1pt>development, sales&nbsp;</font>and&nbsp;<font style=LETTER-SPACING:0.1pt>marketing&nbsp;</font>and&nbsp;<font style=LETTER-SPACING:0.1pt>general&nbsp;</font>and administrative expenses. We may also use a portion of the net proceeds to acquire or invest in businesses, products and technologies that are complementary to our own, although we have no current plans, commitments or agreements with respect to any such acquisitions or investments as of the date of this prospectus. We will set forth in the applicable prospectus supplement or free writing prospectus&nbsp;<font style=LETTER-SPACING:0.1pt>our&nbsp;</font>intended use for the net proceeds received from the sale of any common stock sold pursuant to the prospectus supplement or free writing prospectus.&nbsp; Our management will have broad discretion in the allocation of the net proceeds from this offering.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.35pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0.05pt 10.25pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Pending the application of the net proceeds, we may invest the net proceeds in short-term, investment grade, interest-bearing securities, certificates of deposit or direct or guaranteed obligations of the U.S. government.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 42.7pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>We will not receive any proceeds from the sale of shares of our common stock by the selling stockholder.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:8.9pt 10.95pt 0pt 0in; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>6</font></p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;<a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.05pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:4.6pt 1.8pt 0pt; LINE-HEIGHT:normal' align=center><a name=DOCS2><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>DESCRIPTION OF CAPITAL STOCK</font></b></a></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.45pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.2pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>The following is a summary of all material characteristics of our capital stock as set forth in our First Amended and Restated Certificate of Incorporation, Bylaws and our Series A Certificate of Designation, as corrected, the Certificate of Designation. The summary does not purport to be complete and is qualified in its entirety by reference to our First Amended and Restated Certificate of Incorporation, Bylaws, and Certificate of Designation, copies of which have been filed as exhibits to the registration statement of which this prospectus is a part.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:9pt 0in 0pt 10.3pt; LINE-HEIGHT:normal'><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Common Stock</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.5pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.05pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>We may issue shares of our common stock from time to time. We are authorized to issue 25,000,000 shares of common stock, par value $0.08 per share. As of July 17, 2020, there were 11,752,589 shares of common stock issued and outstanding. The holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders. The holders of&nbsp;<font style=LETTER-SPACING:0.15pt>common stock&nbsp;</font><font style=LETTER-SPACING:0.1pt>are not&nbsp;</font><font style=LETTER-SPACING:0.15pt>entitled&nbsp;</font>to&nbsp;<font style=LETTER-SPACING:0.1pt>cumulative voting rights with respect&nbsp;</font>to&nbsp;<font style=LETTER-SPACING:0.1pt>the&nbsp;</font><font style=LETTER-SPACING:0.15pt>election&nbsp;</font>of&nbsp;<font style=LETTER-SPACING:0.1pt>directors,&nbsp;</font>and as a&nbsp;<font style=LETTER-SPACING:0.1pt>consequence,&nbsp;</font><font style=LETTER-SPACING:0.15pt>minority&nbsp;</font>stockholders will not be able to elect directors on the basis of their votes alone. Subject to preferences that may be&nbsp;<font style=LETTER-SPACING:0.1pt>applicable&nbsp;</font>to&nbsp;<font style=LETTER-SPACING:0.1pt>any&nbsp;</font>shares of preferred stock issued in the future, holders of common stock are entitled to receive dividends on a pro rata basis as may be declared by our board out of funds legally available therefor. In the event of a liquidation, dissolution or winding up of our Company,&nbsp;<font style=LETTER-SPACING:0.25pt>holders&nbsp;</font><font style=LETTER-SPACING:0.15pt>of&nbsp;</font><font style=LETTER-SPACING:0.2pt>our common stock&nbsp;</font><font style=LETTER-SPACING:0.15pt>are&nbsp;</font><font style=LETTER-SPACING:0.2pt>entitled&nbsp;</font><font style=LETTER-SPACING:0.15pt>to&nbsp;</font><font style=LETTER-SPACING:0.2pt>share ratably&nbsp;</font><font style=LETTER-SPACING:0.15pt>in all&nbsp;</font><font style=LETTER-SPACING:0.2pt>assets remaining&nbsp;</font><font style=LETTER-SPACING:0.15pt>after&nbsp;</font><font style=LETTER-SPACING:0.2pt>payment&nbsp;</font><font style=LETTER-SPACING:0.1pt>of&nbsp;</font><font style=LETTER-SPACING:0.2pt>liabilities&nbsp;</font><font style=LETTER-SPACING:0.15pt>and the&nbsp;</font><font style=LETTER-SPACING:0.25pt>liquidation&nbsp;</font>preference of any then outstanding preferred stock. Holders of common stock have no preemptive rights and no right to convert their&nbsp;<font style=LETTER-SPACING:0.15pt>common stock into&nbsp;</font><font style=LETTER-SPACING:0.1pt>any&nbsp;</font><font style=LETTER-SPACING:0.15pt>other&nbsp;</font><font style=LETTER-SPACING:0.2pt>securities.&nbsp;</font><font style=LETTER-SPACING:0.15pt>There are&nbsp;</font>no&nbsp;<font style=LETTER-SPACING:0.2pt>redemption&nbsp;</font>or&nbsp;<font style=LETTER-SPACING:0.15pt>sinking&nbsp;</font><font style=LETTER-SPACING:0.1pt>fund&nbsp;</font><font style=LETTER-SPACING:0.15pt>provisions applicable&nbsp;</font>to&nbsp;<font style=LETTER-SPACING:0.1pt>the&nbsp;</font><font style=LETTER-SPACING:0.15pt>common stock.&nbsp;</font><font style=LETTER-SPACING:0.2pt>All&nbsp;</font>outstanding shares of common stock are, and all shares of common stock to be outstanding upon completion of this offering will&nbsp;<font style=LETTER-SPACING:0.1pt>be,&nbsp;</font>fully paid and nonassessable.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.35pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 13.05pt 0pt 10.3pt; LINE-HEIGHT:normal'><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Anti-Takeover Effects of Provisions of Our First Amended and Restated Certificate of Incorporation, Bylaws and Delaware Law</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.5pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.2pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>We are subject to the provisions of Section 203 of the Delaware General Corporation Law. Section 203 prohibits a publicly- held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a period of three years after the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A &#147;business combination&#148; includes mergers, asset sales and other transactions resulting in a financial benefit to the interested stockholder. Subject to certain exceptions, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or within the prior three years did own, 15% or more of the corporation&#146;s voting stock.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.4pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0.05pt 10.15pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Our First Amended and Restated Certificate of Incorporation and Bylaws, among other things, prohibit cumulative voting in&nbsp; the election of directors. The First Amended and Restated Certificate of Incorporation authorizes the board of directors to issue up to 5,000,000 shares of preferred stock and to determine the rights, preferences and privileges of these shares of preferred stock without any further vote or action by the stockholders, and specifies that the authorized number of directors may be changed only by a resolution of the board of directors. Special meetings of the stockholders may be called only by the board of directors, the chairman of the board of directors or the President or Secretary. The provisions described above could have the effect of making it more difficult for a third-party&nbsp;<font style=LETTER-SPACING:0.1pt>to&nbsp;</font><font style=LETTER-SPACING:0.15pt>acquire&nbsp;</font>a&nbsp;<font style=LETTER-SPACING:0.15pt>majority&nbsp;</font>of&nbsp;<font style=LETTER-SPACING:0.1pt>our&nbsp;</font><font style=LETTER-SPACING:0.15pt>outstanding voting stock,&nbsp;</font>or&nbsp;<font style=LETTER-SPACING:0.15pt>delay, prevent&nbsp;</font>or&nbsp;<font style=LETTER-SPACING:0.15pt>deter&nbsp;</font>a&nbsp;<font style=LETTER-SPACING:0.15pt>merger, acquisition&nbsp;</font>or&nbsp;<font style=LETTER-SPACING:0.15pt>tender offer&nbsp;</font>in&nbsp;<font style=LETTER-SPACING:0.1pt>which&nbsp;</font><font style=LETTER-SPACING:0.2pt>our&nbsp;</font>stockholders could receive a premium for their shares, a proxy contest or other change in our management.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.4pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 10.3pt; LINE-HEIGHT:normal'><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Preferred Stock</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.15pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.1pt'>Pursuant&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>to the&nbsp;<font style=LETTER-SPACING:0.1pt>terms&nbsp;</font>of our&nbsp;<font style=LETTER-SPACING:0.1pt>First Amended&nbsp;</font>and&nbsp;<font style=LETTER-SPACING:0.15pt>Restated&nbsp;</font><font style=LETTER-SPACING:0.1pt>Certificate&nbsp;</font>of&nbsp;<font style=LETTER-SPACING:0.1pt>Incorporation,&nbsp;</font>our&nbsp;<font style=LETTER-SPACING:0.1pt>board&nbsp;</font>of&nbsp;<font style=LETTER-SPACING:0.1pt>directors&nbsp;</font>is&nbsp;<font style=LETTER-SPACING:0.15pt>authorized,&nbsp;</font>subject to limitations prescribed by Delaware law, to issue up to 5,000,000 shares of preferred stock, par value $0.08 per share, in one or&nbsp;<font style=LETTER-SPACING:0.15pt>more&nbsp;</font><font style=LETTER-SPACING:0.2pt>series,&nbsp;</font><font style=LETTER-SPACING:0.1pt>to&nbsp;</font><font style=LETTER-SPACING:0.2pt>establish&nbsp;</font><font style=LETTER-SPACING:0.15pt>from time&nbsp;</font><font style=LETTER-SPACING:0.1pt>to&nbsp;</font><font style=LETTER-SPACING:0.15pt>time the&nbsp;</font><font style=LETTER-SPACING:0.2pt>number&nbsp;</font>of&nbsp;<font style=LETTER-SPACING:0.15pt>shares&nbsp;</font>to be&nbsp;<font style=LETTER-SPACING:0.15pt>included&nbsp;</font>in&nbsp;<font style=LETTER-SPACING:0.15pt>each series,&nbsp;</font><font style=LETTER-SPACING:0.1pt>and&nbsp;</font>to&nbsp;<font style=LETTER-SPACING:0.1pt>fix the&nbsp;</font><font style=LETTER-SPACING:0.15pt>designation, powers,&nbsp;</font>preferences and rights of the shares of each series and any of its qualifications, limitations or restrictions, in each case without further action by our stockholders. Our board of directors also can increase or decrease the number of shares of any series of preferred stock,&nbsp; but not below the number of shares of that series then outstanding. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other&nbsp;<font style=LETTER-SPACING:0.1pt>corporate&nbsp;</font>purposes,&nbsp;<font style=LETTER-SPACING:0.1pt>could, among other things, have&nbsp;</font>the&nbsp;<font style=LETTER-SPACING:0.1pt>effect&nbsp;</font>of&nbsp;<font style=LETTER-SPACING:0.1pt>delaying, deferring&nbsp;</font>or&nbsp;<font style=LETTER-SPACING:0.1pt>preventing&nbsp;</font>a&nbsp;<font style=LETTER-SPACING:0.1pt>change&nbsp;</font>in our&nbsp;<font style=LETTER-SPACING:0.1pt>control&nbsp;</font>or the&nbsp;<font style=LETTER-SPACING:0.1pt>removal&nbsp;</font>of&nbsp;<font style=LETTER-SPACING:0.1pt>management&nbsp;</font><font style=LETTER-SPACING:0.15pt>and&nbsp;</font>could adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:8.9pt 10.95pt 0pt 0in; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>7</font></p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;<a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:4.6pt 400.5pt 0pt 2.6pt; LINE-HEIGHT:normal'><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Series A Preferred Stock</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.45pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.15pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>On February 4, 2020, we filed a Certificate of Designations, Preferences and Rights of Series A 5% Convertible Preferred Stock with the Secretary of State of the State of Delaware, which designated 571,429 of our preferred stock as Series A Preferred Stock with the powers, preferences and rights set forth therein. As of July 17, 2020, there were 321,429 shares of Series A Preferred Stock issued and outstanding.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.5pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.05pt 0in 0pt 42.7pt; LINE-HEIGHT:normal'><i><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Voting Rights.</font></i></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.15pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Except as otherwise provided by Delaware law, other applicable law or as provided in the Certificate of Designations, the holders of our Series A Preferred Stock are not entitled to vote on any matter submitted for a vote of holders of our common stock. The consent of the holders of at least a majority of the outstanding shares of our Series A Preferred Stock will be required to, among other matters, (i) alter, amend or change adversely any rights, preferences, or privileges of our Series A Preferred Stock, (ii) amend our First Amended and Restated Certificate of Incorporation or Bylaws in any manner that would impair or reduce the rights of our Series A Preferred Stock, or (iii) amend, alter, or repeal any provision of the Certificate of Designations.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 42.7pt; LINE-HEIGHT:normal'><i><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Dividends.</font></i></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.2pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Shares of our Series A Preferred Stock accrue annual preferred dividends at a rate of $0.175 per share, which are payable when, as and if declared by our board of directors. The holders of the outstanding shares of our Series A Preferred Stock are also entitled to receive on each share of our Series A Preferred Stock dividends prior to, or simultaneously with, any dividend declared with respect to our common stock equal to the greater of (i) the amount of dividends that have accrued on such share of our Series A Preferred Stock and (ii) the dividend payable with respect to each share of our common stock issuable upon conversion of such share of our Series A Preferred Stock.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 42.7pt; LINE-HEIGHT:normal'><i><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Liquidation Preference.</font></i></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.45pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0.05pt 10.15pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>In the event of a liquidation, dissolution or winding up of the Company, or a Deemed Liquidation Event (as defined in the Certificate of Designation) the holders of our Series A Preferred Stock are eligible to receive the greater of (i) an amount equal to $3.50 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination, or other similar recapitalization with respect to our Series A Preferred Stock) (the &#147;Original Issue Price&#148;), plus an amount equal to accrued and unpaid dividends thereon, or (ii) such amount per share as would have been payable had all shares of our Series A Preferred Stock been converted into our common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 42.7pt; LINE-HEIGHT:normal'><i><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Conversion.</font></i></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.5pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.1pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Shares of our Series A Preferred Stock are convertible at the option of the holder at any time into shares of our common stock&nbsp; at a conversion rate determined by dividing the Original Issue Price by $3.50 per share (subject to appropriate adjustment in the event of&nbsp;<font style=LETTER-SPACING:0.1pt>any&nbsp;</font>stock dividend, stock&nbsp;<font style=LETTER-SPACING:0.1pt>split, combination,&nbsp;</font>recapitalizations, dividends, distributions and certain issuances of common&nbsp;<font style=LETTER-SPACING:0.1pt>stock)&nbsp;</font>(the&nbsp;<font style=LETTER-SPACING:0.15pt>&#147;Conversion Price&#148;). This formula initially results&nbsp;</font>in a&nbsp;<font style=LETTER-SPACING:0.15pt>one-to-one conversion ratio.&nbsp;</font><font style=LETTER-SPACING:0.1pt>The&nbsp;</font><font style=LETTER-SPACING:0.15pt>Conversion Price&nbsp;</font>is&nbsp;<font style=LETTER-SPACING:0.15pt>subject&nbsp;</font>to&nbsp;<font style=LETTER-SPACING:0.2pt>customary&nbsp;</font><font style=LETTER-SPACING:0.15pt>weighted average anti-dilution&nbsp;</font><font style=LETTER-SPACING:0.1pt>adjustments&nbsp;</font>in&nbsp;<font style=LETTER-SPACING:0.1pt>the event&nbsp;</font>of&nbsp;<font style=LETTER-SPACING:0.1pt>certain&nbsp;</font><font style=LETTER-SPACING:0.15pt>dilutive issuances&nbsp;</font>of&nbsp;<font style=LETTER-SPACING:0.15pt>shares&nbsp;</font>of&nbsp;<font style=LETTER-SPACING:0.1pt>our&nbsp;</font><font style=LETTER-SPACING:0.15pt>common&nbsp;</font><font style=LETTER-SPACING:0.1pt>stock&nbsp;</font>or&nbsp;<font style=LETTER-SPACING:0.15pt>convertible&nbsp;</font>securities.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.35pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>We may require the conversion of all of the outstanding shares of our Series A Preferred Stock if the closing sale price of our common stock equals or exceeds $9.00 for a period of five (5) consecutive trading days with a minimum average trading volume of 35,000 shares per day over such period; provided, that, on such date, the shares of our common stock issuable upon conversion of our Series A Preferred Stock are registered for resale under the Securities Act or are otherwise eligible for resale pursuant to Rule 144 thereunder.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:8.9pt 10.95pt 0pt 0in; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>8</font></p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;<a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:4.6pt 9.95pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Notwithstanding the foregoing, prior to the receipt of all approvals, if any, of the shareholders of the Company necessary for purposes of the rules and regulations of the applicable Trading Market (as defined in the Stock Purchase Agreement), our Series A Preferred Shares shall not be converted into shares of Common Stock: (i) in the aggregate into more than 19.99% of the shares of Common Stock outstanding immediately prior to the Issuance Date, subject to appropriate adjustment in the event of a stock split, stock dividend, combination or other similar recapitalization, or (ii) by any beneficial holder (as such term is defined under Rule 13d-3 of the Exchange Act) or &#147;group&#148; (as such term is defined under Rule 13d-5 of the Exchange Act) (such beneficial holder or group, a &#147;Capped Holder&#148;), if (A) the aggregate number of shares of Common Stock issued to such Capped Holder upon such conversion and any Conversion Shares then held by the Capped Holders, plus (B) the number of shares of Common Stock underlying our Series A Preferred Shares that would be held at such time by the Capped Holders (after giving effect to such conversion), plus (C) the aggregate number of shares of Common Stock held by such Capped Holder as of immediately prior to the Issuance Date, would in the aggregate exceed more than 19.99% of the shares of Common Stock outstanding immediately prior to the Issuance Date (without regard to any limitation on conversion pursuant to this Section 5(n)), then such Capped Holder shall be entitled to convert such number of our Series A Preferred Shares as would result in the sum of clauses (A), (B) and (C) (after giving effect to such conversion) being equal to 19.99% of the shares of Common Stock outstanding immediately prior to the Issuance Date, in each case, subject to appropriate adjustment in the event of a stock split, stock dividend, combination or other similar recapitalization. Any Series A Preferred Shares which a holder has elected to convert but which, by reason of the previous sentence are not so converted, shall be treated as if the holder had not made such election to convert and such Series A Preferred Shares shall remain outstanding.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.5pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.05pt 0in 0pt 42.7pt; LINE-HEIGHT:normal'><i><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Ranking.</font></i></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.5pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.3pt 0pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Our Series A Preferred Stock ranks senior to our common stock with respect to distributions upon any liquidation, on parity to any class or series of our capital stock hereafter created specifically ranking by its terms on parity with our Series A Preferred Stock and junior to any class or series of our capital stock hereafter created specifically ranking by its terms senior to our Series A Preferred Stock.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 10.3pt; LINE-HEIGHT:normal'><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>NASDAQ Capital Market Listing</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.4pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Our common stock is listed on the NASDAQ Capital Market and traded under the symbol &#147;BMRA.&#148; On July 17, 2020, the last reported sale price for our common stock on the NASDAQ Capital Market was $10.96 per share.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.4pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 10.3pt; LINE-HEIGHT:normal'><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Transfer Agent and Registrar</font></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.35pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>The transfer agent and registrar for the common stock is Issuer Direct. The transfer agent and registrar&#146;s address is 1981 East 4800 So, Suite 100, Salt Lake City, Utah 84117.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:8.9pt 10.95pt 0pt 0in; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>9</font></p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;<a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 1.8pt 0pt 1.75pt; LINE-HEIGHT:normal' align=center><a name=SS2><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>SELLING STOCKHOLDERS</font></b></a></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.5pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0.05pt 10.25pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>This prospectus relates to the offer and resale of up to an aggregate of 571,429 shares of our common stock from time to time by the stockholder identified in the table below, which we refer to in this prospectus as the selling stockholder.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.1pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>The shares of our common stock being offered by the selling stockholder include shares of our common stock that were issued and are issuable upon conversion of the shares of our Series A Preferred Stock issued to the selling stockholder. For additional information regarding the issuance of the shares of our Series A Preferred Stock and the shares of our common stock issued and issuable upon conversion thereof, see &#147;Stock Purchase Agreement with Selling Stockholder&#148; below.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>The table sets forth certain information with respect to the selling stockholder, including (i) the identity of the selling stockholder, (ii) the number of shares of our common stock beneficially owned by the selling stockholder before this offering, (iii) the number of shares of our common stock being offered by the selling stockholder in this offering, and (iv) the number and percentage of shares of our common stock beneficially owned by the selling stockholder upon completion of this offering, assuming that all of the shares being offered by this prospectus are sold.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 9.95pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.2pt'>The&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.3pt'>information&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.15pt'>in&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.2pt'>the&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.25pt'>table&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.2pt'>and&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.3pt'>accompanying footnotes&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.15pt'>is&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.25pt'>based&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.15pt'>on&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.3pt'>information&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.25pt'>made&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.3pt'>available&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.15pt'>to us by&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.2pt'>the&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.35pt'>selling&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>stockholder. Under applicable SEC rules, beneficial ownership includes any shares of our common stock as to which a person has sole&nbsp; or shared voting power or investment power, and any shares of our common stock which the person has the right to acquire within 60 days of July 17, 2020 through the exercise of any option, warrant or right, or through the conversion of any convertible security.&nbsp;<font style=LETTER-SPACING:0.1pt>The&nbsp;</font>percentage of shares beneficially owned is based on 11,752,589 shares of common stock issued and outstanding as of July 17,&nbsp;<font style=LETTER-SPACING:0.1pt>2020.&nbsp;</font>Unless otherwise indicated in the footnotes to the table, and subject to community property laws where applicable, we believe that the selling stockholder named in this table has sole voting and investment power with respect to the shares indicated as beneficially owned.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.5pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <table width=70% bordercolor=transparent style="WIDTH:70%; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr> <td width=28% style="BORDER-TOP:0px; BORDER-RIGHT:0px; WIDTH:28%; BACKGROUND:#eeeeee; BORDER-BOTTOM:black 1pt solid; PADDING-BOTTOM:0.5pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; BORDER-LEFT:0px; PADDING-RIGHT:0.25pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>Selling Stockholder</font></b></p></td> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:1.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:1.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=15% style="BORDER-TOP:0px; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#eeeeee; BORDER-BOTTOM:black 1pt solid; PADDING-BOTTOM:0.5pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; BORDER-LEFT:0px; PADDING-RIGHT:0.25pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>Shares of Common Stock Beneficially Owned Before This Offering (1)</font></b></p></td> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:1.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:1.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:1.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=15% style="BORDER-TOP:0px; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#eeeeee; BORDER-BOTTOM:black 1pt solid; PADDING-BOTTOM:0.5pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; BORDER-LEFT:0px; PADDING-RIGHT:0.25pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>Shares of Common Stock Being Offered in This Offering</font></b></p></td> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:1.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:1.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:1.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=15% style="BORDER-TOP:0px; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#eeeeee; BORDER-BOTTOM:black 1pt solid; PADDING-BOTTOM:0.5pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; BORDER-LEFT:0px; PADDING-RIGHT:0.25pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>Shares of Common Stock Beneficially Owned upon Completion of This Offering (2)</font></b></p></td> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:1.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:1.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:1.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=15% style="BORDER-TOP:0px; BORDER-RIGHT:0px; WIDTH:15%; BACKGROUND:#eeeeee; BORDER-BOTTOM:black 1pt solid; PADDING-BOTTOM:0.5pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; BORDER-LEFT:0px; PADDING-RIGHT:0.25pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; BACKGROUND:white; COLOR:black'>Percentage of Shares Beneficially Owned upon Completion of This Offering</font></b></p></td> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:1.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /></tr> <tr> <td width=28% style="WIDTH:28%; BACKGROUND:#eeeeee; PADDING-BOTTOM:0.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'><br><font style=COLOR:black>Palm Global Small Cap Master Fund LP</font></font></p></td> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:0.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:0.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=15% style="WIDTH:15%; BACKGROUND:#eeeeee; PADDING-BOTTOM:0.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>571,429</font></p></td> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:0.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:0.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:0.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=15% style="WIDTH:15%; BACKGROUND:#eeeeee; PADDING-BOTTOM:0.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>571,429</font></p></td> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:0.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:0.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:0.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=15% style="WIDTH:15%; BACKGROUND:#eeeeee; PADDING-BOTTOM:0.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>-</font></p></td> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:0.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:0.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:0.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom /> <td width=15% style="WIDTH:15%; BACKGROUND:#eeeeee; PADDING-BOTTOM:0.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right>&nbsp;</p></td> <td width=1% style="WIDTH:1%; BACKGROUND:#eeeeee; PADDING-BOTTOM:0.25pt; PADDING-TOP:0.25pt; PADDING-LEFT:0.25pt; PADDING-RIGHT:0.25pt" valign=bottom> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:right; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=right><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>*</font></p></td></tr></table> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 10.3pt; LINE-HEIGHT:115%'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 10.3pt; LINE-HEIGHT:10.35pt'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:-0.05pt'>*</font><font style='FONT-SIZE:7pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:-0.05pt'>&nbsp;&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Represents beneficial ownership of less than 1% of our outstanding shares.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.3pt 0pt 26.8pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:-16.2pt'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:-1.05pt'>(1)</font><font style='FONT-SIZE:7pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:-1.05pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Consists of (i) 250,000 shares of common stock and (ii) 321,429 shares of Series A Preferred Stock convertible into 321,429 shares of common stock.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.2pt 0pt 26.8pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:-16.2pt'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:-1.05pt'>(2)</font><font style='FONT-SIZE:7pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:-1.05pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Assumes that all shares of common stock being registered on behalf of the selling stockholder under the registration statement of which this prospectus forms a part are sold in this offering, and that the selling stockholder will not acquire additional shares of our common stock after the date of this prospectus and prior to completion of this offering.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.2pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.3pt 0pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>All of the shares being registered for resale by the selling stockholder pursuant to this prospectus were issued and outstanding prior to the original date of filing of the registration statement of which this prospectus is a part.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.5pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0.05pt 10.25pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>The registration of the shares of our common stock set forth in the table does not mean that the selling stockholder will sell or otherwise dispose of all or any of those securities. The selling stockholder may sell any, all or none of the securities offered by this prospectus, and we do not know when or in what amount the selling stockholder may sell its shares of common stock hereunder following the effective date of this registration statement. Information concerning the selling stockholder may change from time to time and, if necessary, we will amend or supplement this prospectus as required by SEC rules.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:8.9pt 10.95pt 0pt 0in; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>10</font></p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;<a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:4.65pt 0in 0pt 10.3pt; LINE-HEIGHT:normal'><b><u><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Stock Purchase Agreement with Selling Stockholder</font></u></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:4.6pt 10.25pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>On February 21, 2020, we entered into a Stock Purchase Agreement (the &#147;Stock Purchase Agreement&#148;) with, and consummated a private placement of 571,429 shares of our Series A Preferred Stock to the selling stockholder. The offer and sale of the shares were not registered under the Securities Act in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.1pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>In connection with the Stock Purchase Agreement, we entered into a registration rights agreement (the &#147;Registration Rights Agreement&#148;) with the selling stockholder, pursuant to which we agreed to file a registration statement registering the resale of the shares of our common stock issuable upon conversion of our Series A Preferred Stock issued to the selling stockholder under the Stock Purchase Agreement.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.5pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.3pt 0pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>As of July 17, 2020, the selling stockholder holds 321,429 shares of our Series A Preferred Stock and has converted the other 250,000 shares of our Series A Preferred Stock purchased under the Stock Purchase Agreement into shares of our common stock.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 10.3pt; LINE-HEIGHT:normal'><b><u><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Board Observer Agreement</font></u></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.5pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:4.65pt 9.95pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>In connection with the Stock Purchase Agreement, we entered into a board observer agreement (the &#147;Board Observer Agreement&#148;) with the selling stockholder. The Board Observer Agreement provides that for the longer of three years following the closing of the transactions under the Stock Purchase Agreement or for so long as the selling stockholder holds any shares of our Series A Preferred Stock, the selling stockholder will have the right to appoint one individual to attend and observe meetings of our board of directors, subject to certain exceptions.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 10.3pt; LINE-HEIGHT:normal'><b><u><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>No Material Relationships</font></u></b></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.5pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:4.65pt 13.05pt 0pt 10.3pt; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Except as described above, there are no material relationships between us and the selling stockholder, and there have been no material relationships within the past three years. In addition, we have been advised that the selling stockholder is not, nor is it affiliated with, any broker-dealer or underwriter.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:8.9pt 10.95pt 0pt 0in; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>11</font></p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;<a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.05pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:4.6pt 1.8pt 0pt; LINE-HEIGHT:normal' align=center><a name=POD2><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>PLAN OF DISTRIBUTION</font></b></a></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.45pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.2pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>We or the selling stockholder may sell shares of our common stock from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods. We or the selling stockholder may sell shares of our common stock to or through underwriters or dealers, through agents, or directly to one or more purchasers. We or the selling stockholder may sell shares of our common stock from time to time in one or more transactions:</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.15pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.05pt 0in 0pt 58.9pt; LINE-HEIGHT:normal; TEXT-INDENT:-16.2pt'><font style="FONT-SIZE:9pt; FONT-FAMILY:Symbol">&#183;</font><font style='FONT-SIZE:7pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>at a fixed price or prices, which may be changed;</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.35pt 0in 0pt 61.1pt; LINE-HEIGHT:normal; TEXT-INDENT:-18.4pt'><font style="FONT-SIZE:9pt; FONT-FAMILY:Symbol">&#183;</font><font style='FONT-SIZE:7pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>at market prices prevailing at the time of sale;</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0in 0pt 61.1pt; LINE-HEIGHT:normal; TEXT-INDENT:-18.4pt'><font style="FONT-SIZE:9pt; FONT-FAMILY:Symbol">&#183;</font><font style='FONT-SIZE:7pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>at prices related to such prevailing market prices; or</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.35pt 0in 0pt 61.1pt; LINE-HEIGHT:normal; TEXT-INDENT:-18.4pt'><font style="FONT-SIZE:9pt; FONT-FAMILY:Symbol">&#183;</font><font style='FONT-SIZE:7pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>at negotiated prices.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.35pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0.05pt 10.2pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>We or the selling stockholder may also sell shares of our common stock covered by this registration statement in an &#147;at the market offering&#148; as defined in Rule 415 under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either:</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 10.35pt 0pt 58.9pt; LINE-HEIGHT:normal; TEXT-INDENT:-16.2pt'><font style="FONT-SIZE:9pt; FONT-FAMILY:Symbol">&#183;</font><font style='FONT-SIZE:7pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>on or through the facilities of the NASDAQ Capital Market or any other stock exchange or quotation or trading service on which our common stock may be listed, quoted or traded at the time of sale; and/or</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.35pt 10.2pt 0pt 58.9pt; LINE-HEIGHT:normal; TEXT-INDENT:-16.2pt'><font style="FONT-SIZE:9pt; FONT-FAMILY:Symbol">&#183;</font><font style='FONT-SIZE:7pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>to or through a market maker other than on the NASDAQ Capital Market or such other stock exchanges or quotation or trading services.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.45pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 42.7pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Such at-the-market offerings, if any, may be conducted by underwriters acting as principal or agent.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.4pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 1.5pt 0pt 10.3pt; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of our common stock, including, to the extent applicable:</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.2pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 61.1pt; LINE-HEIGHT:normal; TEXT-INDENT:-18.4pt'><font style="FONT-SIZE:9pt; FONT-FAMILY:Symbol">&#183;</font><font style='FONT-SIZE:7pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>whether we and/or the selling stockholder will be selling shares of our common stock thereunder;</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.35pt 0in 0pt 61.1pt; LINE-HEIGHT:normal; TEXT-INDENT:-18.4pt'><font style="FONT-SIZE:9pt; FONT-FAMILY:Symbol">&#183;</font><font style='FONT-SIZE:7pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>the name or names of any underwriters, dealers or agents, if any;</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.3pt 0in 0pt 61.1pt; LINE-HEIGHT:normal; TEXT-INDENT:-18.4pt'><font style="FONT-SIZE:9pt; FONT-FAMILY:Symbol">&#183;</font><font style='FONT-SIZE:7pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>the purchase price of the common stock and the proceeds we or the selling stockholder will receive from the sale;</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.35pt 10.05pt 0pt 58.9pt; LINE-HEIGHT:normal; TEXT-INDENT:-16.2pt'><font style="FONT-SIZE:9pt; FONT-FAMILY:Symbol">&#183;</font><font style='FONT-SIZE:7pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.1pt'>any&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.15pt'>over-allotment options under which underwriters&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.1pt'>may&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.15pt'>purchase additional common stock from&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.1pt'>us&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>or&nbsp;<font style=LETTER-SPACING:0.15pt>the&nbsp;</font><font style=LETTER-SPACING:0.2pt>selling&nbsp;</font>stockholder;</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.35pt 0in 0pt 61.1pt; LINE-HEIGHT:normal; TEXT-INDENT:-18.4pt'><font style="FONT-SIZE:9pt; FONT-FAMILY:Symbol">&#183;</font><font style='FONT-SIZE:7pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>any agency fees or underwriting discounts and other items constituting agents&#146; or underwriters&#146; compensation;</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0in 0pt 61.1pt; LINE-HEIGHT:normal; TEXT-INDENT:-18.4pt'><font style="FONT-SIZE:9pt; FONT-FAMILY:Symbol">&#183;</font><font style='FONT-SIZE:7pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>any public offering price;</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.35pt 0in 0pt 61.1pt; LINE-HEIGHT:normal; TEXT-INDENT:-18.4pt'><font style="FONT-SIZE:9pt; FONT-FAMILY:Symbol">&#183;</font><font style='FONT-SIZE:7pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>any discounts or concessions allowed or reallowed or paid to dealers; and</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.35pt 0in 0pt 61.1pt; LINE-HEIGHT:normal; TEXT-INDENT:-18.4pt'><font style="FONT-SIZE:9pt; FONT-FAMILY:Symbol">&#183;</font><font style='FONT-SIZE:7pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>any securities exchange or market on which our common stock may be listed.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.35pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 10.3pt; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Only underwriters named in the prospectus supplement are underwriters of the common stock offered by the prospectus supplement.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.45pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.05pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>If underwriters are used in the sale, they will acquire the common stock for their own account and may resell the common stock from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the common stock will be subject to the conditions set forth in the applicable underwriting agreement. We or the selling stockholder may offer our common stock to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions unless otherwise specified in the prospectus supplement, the underwriters will be obligated to purchase all of the common stock offered by the prospectus supplement. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. We or the selling stockholder may use underwriters with whom we or the selling stockholder have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:8.9pt 10.95pt 0pt 0in; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>12</font></p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;<a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.45pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:4.65pt 10.05pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>We or the selling stockholder may sell our common stock directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of our common stock, and we will describe any commissions we or the selling stockholder will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.45pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.3pt 0pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>We or the selling stockholder may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase common stock from us or the selling stockholder at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we or the selling stockholder must pay for solicitation of these contracts in the prospectus supplement.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.45pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.25pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>We or the selling stockholder may provide agents and underwriters with indemnification against civil liabilities related to any offering pursuant to this prospectus, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us or the selling stockholder in the ordinary course of business.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.4pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 9.95pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.2pt'>Any&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.25pt'>underwriter&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.2pt'>may&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.25pt'>engage&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.15pt'>in&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.25pt'>overallotment,&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.2pt'>stabilizing transactions, short covering transactions&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.15pt'>and&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.2pt'>penalty&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.15pt'>bids&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"; LETTER-SPACING:0.25pt'>in&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>accordance with Regulation M under the Exchange Act. Overallotment involves sales in excess of the offering size, which create a short position. This short sales position may involve either &#147;covered&#148; short sales or &#147;naked&#148; short sales. Covered short sales are short sales&nbsp;<font style=LETTER-SPACING:0.25pt>made&nbsp;</font><font style=LETTER-SPACING:0.15pt>in an&nbsp;</font><font style=LETTER-SPACING:0.25pt>amount&nbsp;</font><font style=LETTER-SPACING:0.2pt>not&nbsp;</font><font style=LETTER-SPACING:0.25pt>greater than&nbsp;</font><font style=LETTER-SPACING:0.2pt>the&nbsp;</font><font style=LETTER-SPACING:0.25pt>underwriters&#146; over-allotment option&nbsp;</font><font style=LETTER-SPACING:0.15pt>to&nbsp;</font><font style=LETTER-SPACING:0.3pt>purchase&nbsp;</font><font style=LETTER-SPACING:0.25pt>additional shares&nbsp;</font><font style=LETTER-SPACING:0.15pt>in&nbsp;</font><font style=LETTER-SPACING:0.2pt>the&nbsp;</font><font style=LETTER-SPACING:0.25pt>offering.&nbsp;</font><font style=LETTER-SPACING:0.3pt>The&nbsp;</font>underwriters may close out any covered short position either by exercising their over-allotment option or by purchasing shares of&nbsp;<font style=LETTER-SPACING:0.1pt>our&nbsp;</font>common stock in the open market. To determine how they will close the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market, as compared to the price at which they may purchase shares through the over-allotment option. Naked short sales are short sales in excess of the over-allotment option. The underwriters must close&nbsp;<font style=LETTER-SPACING:0.2pt>out any naked short&nbsp;</font><font style=LETTER-SPACING:0.25pt>position&nbsp;</font>by&nbsp;<font style=LETTER-SPACING:0.2pt>purchasing shares&nbsp;</font><font style=LETTER-SPACING:0.1pt>in&nbsp;</font><font style=LETTER-SPACING:0.15pt>the open&nbsp;</font><font style=LETTER-SPACING:0.2pt>market.&nbsp;</font>A&nbsp;<font style=LETTER-SPACING:0.15pt>naked&nbsp;</font><font style=LETTER-SPACING:0.2pt>short position&nbsp;</font><font style=LETTER-SPACING:0.1pt>is&nbsp;</font><font style=LETTER-SPACING:0.15pt>more&nbsp;</font><font style=LETTER-SPACING:0.2pt>likely&nbsp;</font><font style=LETTER-SPACING:0.1pt>to be&nbsp;</font><font style=LETTER-SPACING:0.2pt>created&nbsp;</font><font style=LETTER-SPACING:0.1pt>if&nbsp;</font><font style=LETTER-SPACING:0.25pt>the&nbsp;</font>underwriters are concerned that, in the open market after pricing, there may be downward pressure on the price of the shares that could adversely affect investors who purchase shares in the offering. Stabilizing transactions permit bids to purchase the underlying security for the purpose of fixing the price of the security so long as the stabilizing bids do not exceed a specified maximum. Penalty bids permit&nbsp;<font style=LETTER-SPACING:0.1pt>the&nbsp;</font><font style=LETTER-SPACING:0.15pt>underwriters&nbsp;</font>to&nbsp;<font style=LETTER-SPACING:0.15pt>reclaim&nbsp;</font>a&nbsp;<font style=LETTER-SPACING:0.15pt>selling concession&nbsp;</font><font style=LETTER-SPACING:0.1pt>from&nbsp;</font>a&nbsp;<font style=LETTER-SPACING:0.15pt>dealer when&nbsp;</font><font style=LETTER-SPACING:0.1pt>the&nbsp;</font><font style=LETTER-SPACING:0.15pt>securities originally sold&nbsp;</font>by&nbsp;<font style=LETTER-SPACING:0.1pt>the&nbsp;</font><font style=LETTER-SPACING:0.15pt>dealer&nbsp;</font><font style=LETTER-SPACING:0.1pt>are&nbsp;</font><font style=LETTER-SPACING:0.15pt>purchased&nbsp;</font>in a covering transaction to cover short positions.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.4pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.2pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Any underwriters who are qualified market makers on the NASDAQ Capital Market, or any other stock exchange or which our common stock may be listed at the time of sale, may engage in passive market making transactions in our common stock on the NASDAQ Capital Market or such other stock exchange in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the shares of our common stock. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for our common stock; if all independent bids are lowered below the passive market maker&#146;s bid, however, the passive market maker&#146;s bid must then be lowered when certain purchase limits are exceeded.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.45pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.2pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Similar to other purchase transactions, an underwriter&#146;s purchase to cover the syndicate short sales or to stabilize the market price of our common stock may have the effect of raising or maintaining the market price of our common stock or preventing or mitigating a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. The imposition of a penalty bid might also have an effect on the price of the common stock if it discourages resales of the shares.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.35pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0.05pt 10.25pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Neither we nor the underwriters makes any representation or prediction as to the effect that the transactions described above may have on the price of the common stock offered by this prospectus. If such transactions are commenced, they may be discontinued without notice at any time.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:8.9pt 10.95pt 0pt 0in; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>13</font></p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;<a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.4pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:4.6pt 1.8pt 0pt 1.75pt; LINE-HEIGHT:normal' align=center><a name=LM2><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>LEGAL MATTERS</font></b></a></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.5pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0.05pt 10.25pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Certain legal matters, including the validity of the issuance of the shares of common stock offered by this prospectus will be passed upon for us by Stradling Yocca Carlson &amp; Rauth, P.C., Newport Beach, California.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.4pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 1.8pt 0pt 1.75pt; LINE-HEIGHT:normal' align=center><a name=Experts2><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>EXPERTS</font></b></a></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.55pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.25pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>PKF, LLP, an independent registered public accounting firm, has audited the consolidated financial statements of Biomerica, Inc. and Subsidiaries included in our Annual Report on Form 10-K, for the years ended May 31, 2019 and 2020 as set forth in their report on our consolidated financial statements, which is incorporated by reference in this prospectus and elsewhere in this registration statement. Such consolidated financial statements of Biomerica, Inc. and Subsidiaries are incorporated by reference in reliance on PKF, LLP&#146;s reports, given on the authority of such firm as experts in accounting and auditing.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:8.9pt 10.95pt 0pt 0in; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>14</font></p><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </div> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:left; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=left>&nbsp;</font><a href=#TOC><font size=2 face="Times New Roman">Table of Contents</font></a></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.05pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:4.6pt 0in 0pt 10.3pt; LINE-HEIGHT:normal' align=center><a name=IOCDBR2><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</font></b></a></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.45pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.25pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>The SEC allows us to &#147;incorporate&#148; into this prospectus information that we file with the SEC in other documents. This means that we can disclose important information to you by referring to other documents that contain that information. Any information that we incorporate by reference into this prospectus is considered part of this prospectus.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:9pt 10.05pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:34.7pt'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Information contained in this prospectus and information that we file with the SEC in the future and incorporate by reference&nbsp;<font style=LETTER-SPACING:0.15pt>in this&nbsp;</font><font style=LETTER-SPACING:0.2pt>prospectus automatically modifies&nbsp;</font><font style=LETTER-SPACING:0.15pt>and&nbsp;</font><font style=LETTER-SPACING:0.2pt>supersedes previously filed information, including information&nbsp;</font><font style=LETTER-SPACING:0.1pt>in&nbsp;</font><font style=LETTER-SPACING:0.2pt>previously&nbsp;</font><font style=LETTER-SPACING:0.25pt>filed&nbsp;</font>documents or reports that have been incorporated by reference in this prospectus, to the extent the new information differs from or is&nbsp;<font style=LETTER-SPACING:0.2pt>inconsistent&nbsp;</font><font style=LETTER-SPACING:0.15pt>with the old&nbsp;</font><font style=LETTER-SPACING:0.2pt>information.&nbsp;</font><font style=LETTER-SPACING:0.15pt>Any&nbsp;</font><font style=LETTER-SPACING:0.2pt>information&nbsp;</font><font style=LETTER-SPACING:0.1pt>so&nbsp;</font><font style=LETTER-SPACING:0.2pt>modified&nbsp;</font><font style=LETTER-SPACING:0.1pt>or&nbsp;</font><font style=LETTER-SPACING:0.2pt>superseded shall&nbsp;</font><font style=LETTER-SPACING:0.15pt>not&nbsp;</font><font style=LETTER-SPACING:0.1pt>be&nbsp;</font><font style=LETTER-SPACING:0.2pt>deemed, except&nbsp;</font><font style=LETTER-SPACING:0.1pt>as&nbsp;</font>so&nbsp;<font style=LETTER-SPACING:0.2pt>modified&nbsp;</font><font style=LETTER-SPACING:0.15pt>or&nbsp;</font>superseded, to constitute a part of this prospectus.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.4pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 0in 0pt 44.95pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>The following documents previously filed by us with the SEC are incorporated in this prospectus by reference:</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:8.95pt 0in 0pt 37.3pt; LINE-HEIGHT:normal; TEXT-INDENT:-8.5pt'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>&#149;</font><font style='FONT-SIZE:7pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Our Annual Report on Form 10-K for the fiscal year ended May,31,2020,as filed with the SEC on August 31,2020;</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.35pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.05pt 10.35pt 0pt 37.3pt; LINE-HEIGHT:normal; TEXT-INDENT:-8.5pt'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>&#149;</font><font style='FONT-SIZE:7pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Our Definitive Proxy Statement on Schedule 14A, as filed with the SEC on September 24, 2019 (to the extent incorporated by reference into Part III of our Annual Report on Form 10-K for the fiscal year ended May, 31, 2019);</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:8.95pt 10.35pt 0pt 37.3pt; LINE-HEIGHT:normal; TEXT-INDENT:-8.5pt'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>&#149;</font><font style='FONT-SIZE:7pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Our Current Reports on Form 8-K as filed with the SEC on each of June 2, 2020, June 17, 2020, June 29, 2020 and September 2, 2020; and</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.1pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0in 10.3pt 0pt 0.5in; LINE-HEIGHT:normal; TEXT-INDENT:-9.5pt'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>&#149;</font><font style='FONT-SIZE:7pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;&nbsp;&nbsp;</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>The description of our common stock contained in our registration statement on Form 8-A, filed with the SEC on</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'> August 23, 2016, including any amendment or report filed for the purpose of updating such description.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:8.9pt 10.25pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>We also incorporate by reference all documents (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items) filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date the initial registration statement is initially filed and prior to the termination of this offering, provided that nothing in this prospectus shall be deemed to incorporate portions of documents or information &#147;furnished&#148; and not &#147;filed&#148; with the SEC.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:8.9pt 10.05pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>You should rely only on the information incorporated by reference or provided in this prospectus or any accompanying prospectus supplement. We have not authorized anyone to provide you with different information.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:8.9pt 10.25pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>You should not assume that the information contained in this prospectus and any accompanying prospectus supplement is correct on any date after their respective dates, even though this prospectus or any prospectus supplement is delivered or securities are sold on a later date.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:9pt 10.05pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, upon oral or written request, a copy of any document incorporated by reference at no cost. Requests should be made to:</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:8.95pt 1.8pt 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Zackary Irani</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 190.15pt 0pt 190.2pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>Chairman &amp; Chief Executive Officer<br>Biomerica, Inc.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 161.35pt 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>17571 Von Karman Avenue Irvine, California 92614<br>(949) 645-2111</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:8.9pt 10.95pt 0pt 0in; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>15</font></p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.25pt 0in 0pt; LINE-HEIGHT:normal'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>&nbsp;&nbsp;<a href=#TOC>Table of Contents</a></font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.05pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:4.6pt 0in 0pt 10.3pt; LINE-HEIGHT:normal' align=center><a name=WYCFMI2><b><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>WHERE YOU CAN FIND MORE INFORMATION</font></b></a></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.45pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:0in 10.1pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public at no cost from the SEC&#146;s website at&nbsp;http://www.sec.gov.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:justify; MARGIN:8.95pt 10.05pt 0pt 10.3pt; TEXT-JUSTIFY:inter-ideograph; LINE-HEIGHT:normal; TEXT-INDENT:0.45in'><font style='FONT-SIZE:9pt; FONT-FAMILY:"Times New Roman","serif"'>This prospectus constitutes a part of a registration statement on Form S-3 filed under the Securities Act. As permitted by the SEC&#146;s rules, this prospectus and any accompanying prospectus supplement, which form a part of the registration statement, do not contain all the information that is included in the registration statement. You will find additional information about us in the registration statement. Any statements made in this prospectus or any prospectus supplement concerning legal documents are not necessarily complete and you should read the documents that are filed as exhibits to the registration statement or otherwise filed with the SEC for a more complete understanding of the document or matter.</font></p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; MARGIN:0.4pt 0in 0pt; LINE-HEIGHT:normal'>&nbsp;</p> <p style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:8.9pt 10.95pt 0pt 0in; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'>16</font></p> <div style='FONT-SIZE:11pt; FONT-FAMILY:"Calibri","sans-serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt; LINE-HEIGHT:normal' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black'> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div></div> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 10pt; TEXT-AUTOSPACE:; page:WordSection7' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"'>  </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 10pt; TEXT-AUTOSPACE:; page:WordSection7' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; page:WordSection7' align=center><b><font style='FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>$15,000,000</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; page:WordSection7' align=center>&nbsp;</p> <p style=page:WordSection7 align=center><img width=3549 height=600 style="HEIGHT:50px; WIDTH:252px" src=logo.jpg></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; page:WordSection7' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; page:WordSection7' align=center><b><font style='FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>BIOMERICA, INC.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; page:WordSection7' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; page:WordSection7' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; page:WordSection7' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; page:WordSection7' align=center><b><font style='FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>Common Stock</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; page:WordSection7' align=center><b></b>&nbsp;</p> <div style="BORDER-TOP:0px; BORDER-RIGHT:0px; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:1pt; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; page:WordSection7"> <p style='FONT-SIZE:12pt; BORDER-TOP:0px; FONT-FAMILY:"Times New Roman","sans-serif"; BORDER-RIGHT:0px; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; MARGIN:0cm 0cm 0pt; BORDER-LEFT:0px; PADDING-RIGHT:0cm; TEXT-AUTOSPACE:'>&nbsp;</p></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; page:WordSection7'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; page:WordSection7'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; page:WordSection7' align=center><b><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>PROSPECTUS SUPPLEMENT</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; page:WordSection7'>&nbsp;</p> <div style="BORDER-TOP:0px; BORDER-RIGHT:0px; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:1pt; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm; page:WordSection7"> <p style='FONT-SIZE:12pt; BORDER-TOP:0px; FONT-FAMILY:"Times New Roman","sans-serif"; BORDER-RIGHT:0px; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; MARGIN:0cm 0cm 0pt; BORDER-LEFT:0px; PADDING-RIGHT:0cm; TEXT-AUTOSPACE:'>&nbsp;</p></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; page:WordSection7'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; page:WordSection7'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; page:WordSection7' align=center><b><font style='FONT-SIZE:16pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>B. Riley Securities</font></b><font style='FONT-SIZE:16pt; FONT-FAMILY:"Times New Roman","serif"' lang=EN-US>&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; page:WordSection7'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; page:WordSection7'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; page:WordSection7'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","sans-serif"; TEXT-ALIGN:center; MARGIN:0cm 0cm 0pt; TEXT-AUTOSPACE:; page:WordSection7' align=center><font style='FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman","serif"; COLOR:black' lang=EN-US>January 22, 2021</font></p></body>
<!-- EDGAR Validation Code: 0E579198 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )8#=X# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?R'H?\0MR[_H.7WK_,_46^_:1\!Z?)Y<VLQHU5_^&GOA]_T&X_RK\M+GX?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[_H"1_G7K5%'LX=@_MW-/^@F?_@3/)?^&8?A]_T!(_SH_P"&8?A]_P! 2/\
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MR7X)U.W>)K2--W^PM'U.7<]./B[E<FN:E)?<?DKM?^Y1]W[U?J.O[#/@5?\
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M%% !1110 4444 %%%% !1110 4W;3J*+ 'W?NTOS_P!^DHJ>5 /\R3_GH_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ_,^SNB?W*XC4O\ @G;J[>?]EOXT_N5/U>J?04/$;AZMO7Y?5'Q;17U5=_\
M!/?QO FZ.\CG^E<QK'[%7CC1K7[0T6]/]RLO9U?Y#W*/&&0XAI4\7&[\SY\H
MKTW6OV>O&.C_ '],GD_X U<IJ?P]\1:3\UQI-V/^V#5+YHZM'OT<RP6(LZ5:
M+OYHYVBK[:!JL?$FFW2?]L&J![&\7[UM.O\ VS:IYCN52#U4E]Z*]%*RLOWD
MV4F[WIW- HHW>]%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *;MIU%%@&[:7;2T5/+'L ^.26'_5R.G_ ZT+7Q)JMDNV&^
MGC3_ 'ZS**=NB,Y4X3^)7.JM?B=XILHTCBUJXC5?^FC5JVOQZ\>VW*^(;KY?
M]NN HHL^[^\X9Y;@JGQT8O\ [=7^1[5H_P"UEXXTV2-IM2DGV_Y]:[SP_P#M
MY^)-)NI)9HY+I&_@WU\LT5K[6JMI'B8CA3)<5?VN&CKV5C[:TG_@I)=V<>VZ
M\/?:F_ZZ5V>E_P#!132+S8)])\EF_P!O_P"O7YY4W;51Q%9/5W/G:_AOPY6U
M5#E]&_\ ,_4S0_VU/"6J[/.DCAS_ +8_QKO-)_:0\ ZC'D:[;QGT=J_'K+?\
M]'IPD?\ AGD_[[K3ZY67V4?,8GPCRFKK2JRA]S_,_:*U^+_A"]'[K7;5_P#M
MHM;5GXNTC4/]1?PO_P #K\4+'Q!J6FR;H+N>/Z2-74Z;\;/%VD_\>^IW$?\
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M!VW%C<1[?]BLM]T)VNFQJGF2U9Z<*D*BO%W0E%)NI-U',NYH.HHHJ@"BBB@
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M4?5-&E1113.4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "FL@;J*=10! UO&W6-#_P !K/OO
M#FFZC_Q\6<,GU05KT4%QG.#O%M'G>J? SP=K#.USI*/NZ\+7(:E^QO\ "_4]
M[2:%^];^/?7N=%9NG![H]FAGF:8;^#B9Q]),^3=?_8)\*31N;!!&W\%>9^(/
M^">>H2QR'3[R-&_@K[^HK-X>F^A]1A>/^(,)\.(YO\6I^8>K_L!^-]-A,J2Q
MSK_TSKSWQ-^S#XT\-0>9)8R3[?[B-7Z^,JMUJI-IMI<?ZVWA?_>0&N?ZE2Z'
MU>%\6LYIO]_",UZ6/Q.U+P-X@TGY;C2;J/\ [8-6=)I6H0?-+93Q_P"_&U?M
MM<>%=(O(3'-IMJZM_P!,EKCO$GP%\(>(K3R9=,@C'^PBUE+!/I(^PPOC%2DT
ML3A6EW4KGXXR1R1_ZQ-E,W>]?J/X@_8:\#Z\O^K-N_\ TSKS_P 0?\$[=#CM
M)'TV_D>7^!*QEA:R>FQ]CAO%+(*]E4E*+?='Y\45]7:]^P3XJMT?[ F]Z\[U
MC]C_ .)NCL_F:-(4^M92IU(_9/LL-Q9DF*_AXJ'S:7YGBM%=;JWPH\3Z/(\=
MUIDZ,O\ L-7,S6ES:R>7);SHR_[#5E*7+K)6/I:6)HUU>E-->3(**5@Z_>C<
M4F[WIJ29TA1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *=YDB_=DD_P"^Z;14N*8K7-71_%&J:%)OL[N>
M/_MHU=MH?[1OCOP[(C66KR1LOM7FE%-7CI%V//Q&783%*U>E&7JD?2^@_MV>
M/[61%O[OSQ7L'@W_ (*'6$%OMURTDE?VKX(HV^U;*M6CM+[SY#&\!\/XY6EA
MU'_#I^1^GWA[]O+P/KL\<.)+=V_YZ5Z_X=^-'A7Q&@\C58$8]G=:_&-"T/S1
MOLJ['K6I0?ZJ^FC_ -R1JVCC*D?B5SX;'>$>65E_LE65-^?O'[=0Z_IMQ_JK
MZU;_ '95J]'*LGW6W5^+WACXO^*/"MQYEOJTS[?[\C5Z_P"'?VZ_&^A1I$<7
M"?\ 32NA8V'VD? X[PCS.B_]DK1J>NA^H]%?!WA'_@H7//)'_;%I'"O\=>U>
M'/VVOASK21QW&I"UN&_Y9XKIC6IRZGP./X'S[+W^\PSE_AU_(^AZ*X7P[\8O
M"?B@)]@U:"3=T^=:[".\@F7=',C?\"K9-25T?&UL+7PTN6M!Q?FBU130V[I3
MJ9S!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !4,D*R##*K_6IJ* .=O/ >@Z@
M[-/IL#LW4[:YS4/@'X%U3+3>'K3<W^Q7HM%3RI]#OI9AC*/\*M*/HVOU/F_Q
MG^Q7X0\2/NM8X['_ (!_]:O*M>_X)MVMT7DL/$/D_P#3/RZ^Y:*QEAZ4MXGU
MF#XXX@P*4:.)=EWL_P S\RO$G[!GB/1]_P!GDDNMO^Q7DFL?LZ^/=)N9(O[#
MN'1?XXTK]CF56ZU"UK W6&,_\!K"6#IOX=#[;!^+6;X?^/3C4^]?D?B;JGP_
M\2:/G[9I,\&W_8K!FAE@_P!9&Z5^UGB'X:^'/%&?M^F029_V%K@-9_9(^&FM
MPLL^A1[_ ._FL)8.7V9'V^"\8,))+ZY0DG_=L_SL?D;NIU?HSXN_8#T"Z9SH
M^R"O(=<_X)X^*H9))+&^CD3^",UA+#U8K:Y]Y@_$3A[%J[K\G^+0^1**]O\
M%'[(_C;POYGF6LD^W_GFE>6ZQX'U[1+KR+K2KH/_ -<&K%\T5[RL?:X3-\!C
ME?#5HR^:,*BIY;&[M_\ 6VDD?^^E5MU*YZRDI:ICJ***8PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA_\ M4>#O'OD+#=I:O)VDD6O6K75K'4$W6]W#-_US=6K\/(+ZYM3^ZN)(/\
MKF^VO1/A_P#M!>+?A_.C6E]/,B_P22-79'&V^-'XWFWA#!WGEE>W:,E?\?\
M@'[(45\%?#K_ (*#3S2)'XD@CA"_\M*^G_!'[2'@?QV((].U:-IY/X)/EKMA
M6A4^%GXQFW!^=9.W]9H-I=5JOO/5J*@CN(YON.C_ .Z]3UN?%A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)Q%*-5224E<^?JYS1HU'!Q>A^RWVB/\ OI_WW1]HC_OI_P!]U^-/_#7GC_\
MZ#4__CW^-'_#7GC_ /Z#4_\ X]_C6_\ JIB?YU^)E_;U#^5G[+?:(_[Z?]]T
M?:(_[Z?]]U^-/_#7GC__ *#4_P#X]_C1_P ->>/_ /H-3_\ CW^-'^JF)_G7
MXA_;U#^5G[+?:(_[Z?\ ?='VB/\ OI_WW7XT_P##7GC_ /Z#4_\ X]_C1_PU
MYX__ .@U/_X]_C1_JIB?YU^(?V]0_E9^RWVB/^^G_?='VB/^^G_?=?C3_P -
M>>/_ /H-3_\ CW^-'_#7GC__ *#4_P#X]_C1_JIB?YU^(?V]0_E9^RWVB/\
MOI_WW1]HC_OI_P!]U^-/_#7GC_\ Z#4__CW^-.7]KSQZO_,:G_\ 'O\ &C_5
M3$_SK\0_MZA_*S]D_M4"_P#+:/\ [[%'VR#_ )[1_P#?=?B/JO[1WQ,U*^DN
M(O%%Q O]P;JI_P##0/Q/_P"ALN__ !ZMEPE7ZU%^)']O4OY6?N)]L@_Y[1_]
M]T?;(/\ GM'_ -]U^'?_  T#\3_^ALN__'J/^&@?B?\ ]#9=_P#CU'^J-?\
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M_P#Q[_&C_53$_P Z_$/[>H?RL_9;[1'_ 'T_[[H^T1_WT_[[K\:?^&O/'_\
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M%%% !1110 445@:QXTT/P^'.H:E;VH3[V]^E4HN3M%7$VHZLWZ*\2\8?M9>
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M9$C^;^]]:C_X:\\?_P#0:G_\>_QK[3_5/%?SK\3YS^W:"=N5G[+?:(_[Z?\
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MY_&C_5?&^0?VWAC]9&N(U_C7\Z;]HC_OI_WW7X\Z]^V=XXUF^^T6^I3P1?\
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M_CW^->E_JIB?YU^)Q?V]0_E9^RWVB/\ OI_WW1]HC_OI_P!]U^-/_#7GC_\
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M]E!!')823;?O_P"<US2X9QZV29O'.L*]S].:*_/K1?\ @J?9W4WDW7AKR_\
M;W__ %Z]-\'_ /!0;POXA_X^[>.R_P"!_P#UZX*F1YA25Y4SJAF>%F[*9]<4
M5XYX:_:E\ >(1L&NP02>DCK7?Z7X^T#6_P#CRU:WG_W9%KR:F&K4OC@U\CNC
M6IS^&29TE%-5E;D4ZN<V"BBB@ HHHH **** "BBFLVU<T ,::./[SJOXTW[1
M'_?3_ONOS9_:\_:>\1^$OB-?Z/H^K20>4_\ JXZ\/_X:\\?_ /0:G_\ 'O\
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MNK2)_G^]7+BN'*^$HRK3FK(WHYQ2KU%3C%ZGZ$T4U?NTZODCW@HHHH ****
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M]:/[/@]:Z%PQ@%W,_P"VL5Y?<?I,W_!1C3/,_P!7'L_S[T?\/&M-_P"><?\
MG\:_-O['%1]CBK?_ %=P'8Q_M?%=S])/^'C6F_\ /./_ #^-'_#QK3/[D=?F
MW]CBH^QQ4?ZNY?V#^U\7W/U$\+_\%$/"=Q _]J2) _\ !_G-:_\ P\(\ ?\
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MJ*&^Y0!ZE^R;H;:Y\?M!A\O?%O\ G_2OVHL[=;6UAB3Y51545^6?_!/?P?\
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MA)_WPU'V/4/^?%_^^&HNNX#:*;MG_B@^>AF:+_6?)3 =14:W$3?\M*<LBM0
MZBBB@ HHHH **** "BBB@ HHHH *CDAW?,OR.OW)*DHH ^H/V/OVK]3^&OBJ
M/1=>NY+K1[C;"B2/]ROU3TC5H-8TV"^MWWPSHKK^-?@4WRSQW"_?B^=*_3__
M ()^_&]_&W@?^Q]8O-^H6_RPQO\ W:_.^)<KCR_7**UZGUF38V5_J]1Z=#[&
MHHHK\X/L0HHHH ^5O^"A'BJ7PQ\'':&38\S[*_*-9/M$DEPWWI?GK]!O^"F/
MBY+GP_;Z+YGSH_\ JZ_/>W7;!'7[%PU1]G@$WU;/S[.)J>*:70DHHHKZD\,*
M*** "BBB@ HHHH *]6_9;\%R^,/B]H5PJ;XK>;>__?5>3R?ZMZ^UO^"8_@_^
MU-8U/4KB/Y+7[GZ5Y6:5_JV#J5/+\SNP-/VV(A'S/TFLX_+M88Q_"JU9HHK\
M)/T\**** "N0^(7Q(T3X;Z'/J6L7D<"1H75&?&^N5^.W[0&@_!+PY/>7T\<E
MWL;9!OK\G_C5^T-XC^.&N7=Q>7<D>DL_[FWWU]-E.2U<P?M)>[!=>_H>+C\R
MAA%RQUD>R?M&_MX:Y\1M^C^&7DT>W1V3SX_X_P!:^4]0NKG7+K[5J4\EU=_\
M])'J..-8ONTZOUG"X.A@H*%&-E^)\)6Q%7$2YJCN%%%%=ASA1110 4444 %%
M%% !110S;?O4 %%1K)YORP_._P#SSJQ'I.LW'^ITF>?_ *YQM2NEN!'17;>&
M?@;XS\51QM#I-U!N_P">B-_A7I6B_L)_$'6XTDCWIN_V*XZF-PU'XZB1T0P]
M:I\,&?/]-9MM?5UK_P $T?B'<+F34XX#6IH__!,[QK'<?Z9JT;Q5Q2SG+X_\
MO4=7]FXI_8/COSDH\Y*^ZO\ AVOJ_P#S_P ?^?PH_P"':^K_ //_ !_Y_"LO
M[=R__GX5_9F*_D/A=9%:G5]D>(/^"9_B^23_ (E^K1HE9+?\$RO'^S_D,QUH
MLZR]J_M43_9N+_D/DVBOI2^_X)Z?$:Q=U:?S-M<+KW[*/CKP_)(LEI/-L_V&
M_P *ZJ>882I\%1,PEA*\-X,\EHK4UCP7XGT.Z^SS:%=_+_RT\AJRY+6^M_\
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MU^W93E\<OPZI_:>K9^:X_%O%UG+[*V"BBBO:/."BBB@ HHHH **** "BBB@
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M&\CC9=)NDW?[#5E*K3C\4E]Z+5.;V1QM%>M:?^RCXZU*#SEM)T_X W^%6/\
MAD7Q[_SPD_[X;_"N?Z]AMG41K]7K?R,\=HKV+_AD7Q[_ ,\)/^^&_P *AO/V
M3_'5G#YS6D[_ / &_P *?UW#;*H@^KUOY&>1T5VS? WQFLDD?]DW7R_[#5S^
MJ>!_%6DW'DR:%=/M_P"F#?X5O&M3EI&2^\R=.:Z&314S:/KD7^LTF=/^ND;5
M799[?_70>1_UTK6Z>Q ZBFK(K?=DIU, HHHH **** "BBB@ HHHH CDA67Y6
MKIO ?Q*\1_#+58+S1=2GM;>)][P;V^>N=HJ9QC4BXS5T5&3B^:+L?J+^S+^W
M-HWQ,\C0]>V:=J"HJ+-(_P#K&KZYBE6=%DC;<C5^ -O-/IM]!?6<CP7<#[T\
MM]E?HS^Q+^V1_P )9';^#?%EQ_Q-4^2&=^]?FF=Y J*>)PB]U;K_ "/L,MS7
MVC5&N]>C/NJBF*RRQ[E^96I]? GU84444 %%%% !1110 4444 %%%% !1110
M 4444 %%%9/B'7[/PWI4]_?3I!!"A8N]-)R:26HMM6<%^T!\8=.^#_@#4M3F
MNDCU#R6^S1_Q,U?C7X^\>7WQ0\57?B#4)'WRNWR5ZE^U=^T!??&/QW?6JSR?
MV?9.R0^6_P E>'JNVOV+(LK67T>>?QRW\O(_/<TQKQ53EC\*'4445]0>*%%%
M% !1110 4444 %%%% !1110 57OE9H/E_OK5BFLNZ@#]4_V!OB-;ZY\-;30F
MGWW%HGW/RKZRK\J/^"<7C1-!^*%_9WD^R*X^1*_516#J&7HU?BV?X;ZMCII;
M/4_1LKK.MAHWZ#Z***^=/7"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O<6\5S'LE1'0
M]FKSOQG\ ?!WC2&;[5I,"7#C_7;.:],HJ914E9G9AL9B,'-5,/4<&NSL? 7Q
M,_X)ZSVL=WJ&@ZEYV/G2WV5\I>*_A'XI\%22?VCI,\$2_P#+38U?M57.>*/
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MBTDLKB)]GER5^CX',</F$.:C+7JNJ/D,5A*N%ERU$5:***],X@HHHH ****
M"BBB@ IK+NIU% 'TC^Q'\?=2^&?CN#P[-/\ \22Z?YWD?Z5^L^GWT.I6D=S;
MOOAE7<KU^ OVJ?39([BUD\B577]Y'7[&?L@_$:/QM\)])ADE\V]M851Z_-^*
M, DXXN"WT?\ F?7Y'BG*]"3]#WFBBBOSP^N"BBF22>6C,>@H ^.O^"A/Q';1
M?!?_  CZR;/MJ?XU^7EC'Y<&W_;:OK+_ (*.^-$\2_$S3;6SD_=6NY'KY57M
M7[5D.'^KX"'=ZGYQFE5U<5+L@HHHKZ$\D**** "BBB@ HHHH **** "BBB@
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M_GW^0?V#+^<_$;_A#=:_Y])_^_#4?\(;K7_/I/\ ]^&K]N?^%0>$/^@#:_\
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MS=;,\97_ (E1GLT\%AZ?PP1@VO@W0K.-(X=)L45?2!:N+X?TU>EA:C_MBO\
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MG#$);:,^IR*M:<J7<^BZ***_-#[0**** "BBB@ HHHH **** "BBB@ HHHH
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M6,J>RP\Y>1^7DVH-K-U/>-]^69J*KV*[8-O^VU6*_>;6T1^7L**** "BBB@
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MB99_%3P18:Q;.N]T7>E>A5[R?,KH_A7%8:K@Z\\/65I1;37H%%%%,Y0HHHH
M***CDD\J-W;HM 'P%_P4?^(#63V_A_S/DN$^Y^=?GO:Q^5!MKZ@_X*&>*(O$
MOQAM%MY/W5O\E?,M?M^2451P%-=6KGYIF51U,5-WV"BBBO</-"BBB@ HHHH
M*&[T4UO]70![-^R+X-;Q1\7M%O/+W_99M_\ X]7[,6Z[84'HJU^;O_!,;P:F
MIZEJ>J7"?\>OW/TK]*:_(^)Z_M,;[/\ E5C[W):?)AN;NPHHHKY ^@"BBB@
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MU'P;_P"2T^$_^OE?_0JPK_PI^C_(VH?Q(G[HV'_(/M_^N2_RJU56P_Y!]O\
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O@?_@J5IL<?A'2;P/\
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MQ;!KFJ6GF:)"ZO\ /]WY:\?^#/PIU?XQ>.+#3=-@D^SQ3+YTG^SNK]EOA/\
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M*L<XQCA8==6?5Y'AN9NO+IL:5%%%?FI]D%%%% !1110 4444 %%%% !1110
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MK4Z:Z(^UR&#5*4WU)J***^#/J#EOB)XB3POX2U*];^"%O_0:_#?QE=-?^/\
MQ#=-)O\ -N&?_P >K]8_VY/%3>%/@S=W"R;&?Y:_(B2;[9=3W7_/5]]?I_"=
M#DHSK/KI]Q\5GE6]2-/L.HHHK[P^7"BBB@ HHHH **** !N]?3G_  3U\%IX
MR^(TEPWW+)]_\J^7[B3;'7Z'_P#!-?P*VAV^IZHR?\?2+7A9Y6]A@*C6[/3R
MVG[3%0\C[UC3:BK_ ':?117XB?I04444 %%%% !1110 4444 %%%% !1110
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M]+R_#_5\/&+W>K"BBBO$/2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "L#QNVWPGJQ/\ S[2?^@FM^N0^*EXEA\/M>FD?8JVDG_H-:4TY
M5(I=T1/X6?B?\4KJ*\\?ZDT/W/.;_P!"KFZ;J5UYGB/5I&??_I$G_H5-\Y*_
MH2$>6$8]DC\GD[R;)**C\Y*/.2K))**C\Y*/.2@"2BH_.2CSDH DIK?ZNF^<
ME-DN%^[_ 'J!'V!_P3G\$IXB\32:DW_+J_\ A7ZCJNU<5\2_\$S?"+Z#X'U:
MZE3YK@KM>OMROQCB"M[;'S[(_1LIIJGA8M=0HHHKYL]@**** "BBB@ HHHH
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MJJF!]VGU^'XG$5,55=6H[MGZ71HPH05.&R"OG[]LKX>?\)Y\*;M=F_[*C/\
M^.U] UA>,M/75/"VIVC)O\VW=?\ QVGA:SH5X58[IA7IJK3E!]4?@O,OE:C=
MV_\ SR=DIU=1\6O!LO@/XA:E8R?\M9F?_P >KEZ_?:<U4@I1V9^5RBXR<7N@
MHHHK0D**** "BBB@ H;O110!]"?L/_$;_A#?B=INC^9L^V/7Z]PMNC1O]FOP
M:^'>M?\ "+_$+1=8\S9]GF7]Y_P*OVX^%7BH>,_ NDZL'W_:(5/_ ([7YCQ7
MA^2K"NEH_P S[3(ZRE3E2;U1V-%%%?!'U(4444 %%%% !1110 4444 %%%%
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M04444S4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[21-"1U\Z>1-E?K3\'?@_HWP@\*VNEZ9!&CH@\R4+]ZOD\ZSF&!@Z-)WJ/\
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M***\H[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5GWTWRP;[(_'G]H3Q,WC#XH7=\TF_P#?,G_CU<#1<7DNI:M?S3?._P!HD_\
M0J*_H"E3]E3C371'Y3.3G-R84445J0%%%% !36_U=.J&Z;;!_P #6F@/M?\
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M^<7_  \HU?\ Y\(_\_C1_P /*-7_ .?"/_/XT?ZNYA_*']KX7N?H[17YQ?\
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M6?UW&2FE*+NF%%%%!04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?FEY*4>2E'^K6 _E8?VQB^Y^EO\ P\HT#_H&_P#C_P#]>C_AY1H'_0-_\?\
M_KU^:7DI1Y*4?ZM8#^5A_;&+[GZ$ZU_P5,L--NO*M_#7VE/[^_\ ^O69=?\
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M:_CQYD;\I7Y9^=/>3R7EU)Y]W*[.\DE==\7OB1J?Q:\>:EJVI3R3Q><WV?\
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MO^?]/^_BT?\ #6/@;_G_ $_[^+7F_4<3_(SM^LT?YT>V45XG_P -8^!O^?\
M3_OXM'_#6/@;_G_3_OXM'U'$_P C#ZS1_G1[917B?_#6/@;_ )_T_P"_BT?\
M-8^!O^?]/^_BT?4<3_(P^LT?YT>V45XG_P -8^!O^?\ 3_OXM'_#6/@;_G_3
M_OXM'U'$_P C#ZS1_G1[917B?_#6/@;_ )_T_P"_BUC^(/VTO F@_P"LN]_^
MY(M5' 8J3LJ;$\50CJYH^A**^3]9_P""B'P]T:#>WF2?[E<EJW_!3SP9Y+BQ
MLY'?_;KJCDN/GM29A+,,-'[:/MVJMY?P6$)EGF2!!U+U^:'BC_@HWKEU)/\
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M_P#A-:W2R;_*"I7OE?@.)HO#UI4I;IGZG1J*M3C475!1117,;A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,959=I^
MZU/HH _/[]MW]G7[#-)XJT.T_=O\]QY:5\2U^WOC#PS;>+O#E]I%US%=1LAK
M\BOC]\,Y?A=\1=2TA4D^RH^Z-Z\C%4N1\ZV9_7/ACQ5+,L,\KQ4KU*:]U]X_
M\ \WHHHKC/W<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]\^ _PK?QQH
M-Q<B+<JO][_/UKP55:21(U^\WRU^F7["O@>7P[\,7FOK95N;AP067'RXS_6M
M:,74G;R/SCCS.7DN4NM!^\Y)(^IZ***]X_A8**** /G#]MCQZ/"GPOO+(2;/
MMT3+^AK\A;5=OF?[3L]??W_!4#Q@J6^B:; _S_-O_6O@6-=L=?L'#5#V.!4[
M:RU/S[.*OM,3;L.HHHKZL\,**** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ_X*3^-)?#'P_P!,MX7Q]J=D:OLTG;7YA_\ !2#QF/$&N6^E>?O^RO\ ZO\
M.OHL@H>VQ\+[+4\C-:BIX67F?&\:_P 7][YZ=35_U=.K]I/SD**** "BBB@
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M]MCYI?9T/T3*:7L\+%]PHHHKYH]D**** "BBB@ HHHH **** "BBB@ HHHH
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M&E3JU5[9VBC[=\&>$[+P7X;L=(L8TCM[6)8QL]JWZ^7/^&[_  A_?C_[[_\
MKT?\-W^$/[\?_??_ ->OR665X^3<I4VVS[U8["Q5E,^HZ*^7/^&[_"']^/\
M[[_^O1_PW?X0_OQ_]]__ %ZG^R<;_P ^V/Z_AOYSZCHKY<_X;O\ "']^/_OO
M_P"O1_PW?X0_OQ_]]_\ UZ/[)QO_ #[8?7\-_.?4=%?+G_#=_A#^_'_WW_\
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MBBODCW@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KY$_;N^%$?B#P>FM6%GOOX3^]>.OKNN=\=:/%KOA+4K.9
M-^^!Q_X[652"J0<6?0\/YI4R;,J.,IOX6K^:/Q'9&CD>-OO+25TGQ!\,W/A7
MQ;J5G<1[#YK[/^^JYNO 75,_T(H58UZ4:L'=-7"BBBF;A1110 4444 %%%%
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MM]<^(J>QHSJ=D:TH>TJ1CW9^M_P9T9M!^&F@V3#:T=LH_P#':[.ZE^SPR/\
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M8']B/PG_ ,(E\#])MVCV3/\ ,]?)\2XCV."Y4]9.Q[N34E4Q-WT/H2BBBOR
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M_5/^>LS?^A5^A\)4'S5*S]/U/D<^J*T:?S,^BBBOT@^0"BBB@ HHHH ****
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M1.J]DOQ-\]J6I1AW9QB]J***_43XD**** "BBB@ HHHH *C;YKNT7^],J?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !44T0FC9#T:I
M:* \S\M/VYO#B^'?BN/+^Y,F^OF^OLK_ (*)6L3>+K";^+97QFM>!67+5DC^
M^."<0\3P_A9RWY;?<.HHHK,^X"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KW_\ 9/\
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M/"P3"BBBO#/3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO FR&-=J)5FOPS&8JIC*TJU1ZL_3</0AAZ:IPZ!1117&= 445%(_EQNW]U:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO1:_ ,7+FQ%1^;_,_5<.N6E%>2"BBBN0W"BBB@ HHHH **** "BBB@ HHHH
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M  U5\.?^@['^5'_#57PY_P"@['^5?B]]LOO^?N3_ +[H^V7W_/W)_P!]TO\
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MA\#7Q,>>G'0^!MR_WZ-R_P!^OO?_ (=16O\ T-G_ )#_ /K4?\.HK7_H;/\
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MW:UJ^-_^"@WQN7P?X'_L'2KO_B:W'WHXWKNP6%EC,1&C'JSFQ-98>E*H^A\
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MYGS.>5.6C&FNIS:]J***_4CX@**** "BBB@ HHHH *V/ -BVJ?$;P]9K'O\
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MWU>IJV/'VG_V-\0M=T]?D^SS,G_CU8]?O<9<T5)=3\NE'E;3"BBBJ)"BBB@
MHHHH **** /0/V?_ !U_PK[XH:3-_!<3*G_CU?MEHMVE_H]C<QG<DL*MG_@-
M?@CI]U_9NN6%]_S[OOK]C/V2/B-_PL?X56-YYF_RD5/_ !VOSWBS"MQAB$MM
M&?69#62<J3]3W.BBBOS8^Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:3;'_O?)7Z0_\$UOAX_AGP[JFJS1Y^V!=C_E7YS:?I-SXBU*#3[/Y[AIE_\
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MUNX3YY)/OU]25%'&L,:HORJM2U^&XK$U,96E6J;L_3*%&.'IJG'9!1117(=
M4444 %%%% !7Y(_\%"O$;ZA\=GLXWWVZ"OU5\5:A_9?AV_N_^>4+-_X[7XI_
MM">)F\8?%"[OFDW_ +YD_P#'J^XX5H\V)E5[(^9SRHHT53[G JNVBBBOU,^(
M"BBB@ HHHH *Z3X5Z;+JWQ4\-6\<>]&N%W_]]5S;=Z]T_8O\-MXC^*%I(L>_
M[/,O_H0KDQ=3V5"=1]$;X>//5C'NS]>?#6FQ:/H=C:PIM1(EX_X#6M4-NNV&
M,>B+4U?@#;;NS]52Y59$<TJPQO(WW5K\B/V^?%G_  D'QVGCAGWVD/R5^JGQ
M#U+^R?!>KWG_ #RMV;_QVOQ%^)GBIO&GCB_U!OX9F_\ 0J^ZX3H<U>=?HE;[
MSY?/:W+3C2[G.T445^H'Q84444 %%%% !1110 5K>!]#7Q1XPL-+:/?YLR_^
MA5DUZM^R7X=E\0?'K05:/?;[_G_\=KFQ%3V5&=3LF:T8\]2,>[/UW^#FAKX<
M^&^A:>J;/*MEXKMJKV<*V]K%&GW555%6*_ :DG4FYOJ?JT8\L5%= HHHK,H*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \-_:\\5_\(?\ !_4KK[1Y.4VU^.5]<?;]8N[S[_FOOK](/^"DOCB)/ ?_
M  CJO\[_ #O7YJV:[8(UK]<X7H>SP;F]Y-GP.=5.?$<JZ(FHHHKZ\\ ****
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M@ HHH;[E 'HG[,>F_P!L_'[PW;M]QYJ_;33[=;2Q@A3[J(JBOR;_ &#?!_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4O\ G^D_[[:C_53#_P X?V[6_E1^RO\ PUCX&_Y_T_[^+1_PUCX&_P"?]/\
MOXM?C5]LU+_G^D_[[:C[9J7_ #_2?]]M1_JIA_YP_MVM_*C]E?\ AK'P-_S_
M *?]_%H_X:Q\#?\ /^G_ '\6OQJ^V:E_S_2?]]M1]LU+_G^D_P"^VH_U4P_\
MX?V[6_E1^RO_  UCX&_Y_P!/^_BU#=?M<>!K6"21KY/E_P"FBU^.'VS4O^?Z
M3_OMJ;]JU!OO7\G_ 'VU"X4P_P#.']NU_P"5'ZRR?M\> $DD7S#\M5=1_P""
M@WP_T^WDE+NX6ORBW3_\]Z/WK?*TF]*Z%PO@>K?WF7]MXGR/TOO?^"GG@58?
M]%M))):\Z\;?\%*6OI/^)#')!_GZU\)_9XO^>:4Y8U7_ )9UV4^'<OIN_)<P
MJ9MBIJR=CWCQ?^W!\3_%'F1QW[QV[?Y]:\9\1>)M5\977VC5+N=Y6_VVK/HK
MVJ.%H8?^%!(\VI7JU?CDV-CC5:=11748!1110 4444 %%%% !1110 V1ML>Y
MJ^B/V,/V?Y/BO\0DO=4MY/[)M75TDV?)\M>4?"'X4ZK\:/&-II.FP2/9,Z_:
M)-GW/FK]CO@G\(M,^#O@>QT*PC3,2+ODV?,6KY//\V6"I.C3?[R7X(]W*\"\
M3/VDOA1W>G:?%IMC!:Q?ZJ)%1?PJW161XFU0:+X?OKYO^6,3/7Y"KR=NK/OM
M(H_,7_@HAX\_M+XH3^'5?>L5?):KMCVUZ1^TMXH_X33XQ7^J>9OW2M7G-?N^
M6T?J^$IT[=#\PQE3VM><O,****],XPHHHH **** "BBB@".X;;'7Z._\$U/!
MK:#H.J7S1[/M07^E?F]?-MCC_P"NJ_\ H5?LU^R/X6BT'X.Z+.L>R6XA5_\
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MAK6J>9O\V9O_ $*N7K]]P=)4,/"FELC\LQ%3VE:4O,****[#G"BBB@ HHHH
M**** &[?W\$G]U]]?6GPS_;D_P"%:^&;?2;./[J?/7R;3?+3UKBQ6#HXR*C6
M5TCHHXBIAVY4W9GV]_P\DO?1_P#/XT?\/)+S_II_G\:^(?+3^Y1Y:?W*\[^P
M\!_S[.O^TL5_.?;W_#R2\_Z:?Y_&C_AY)>?]-/\ /XU\0^6G]RCRT_N4?V'@
M/^?8?VEB_P"<^WO^'DEY_P!-/\_C1_P\DO/^FG^?QKXA\M/[E'EI_<H_L/ ?
M\^P_M+%_SGV]_P /)+S_ *:?Y_&C_AY)>?\ 33_/XU\0^6G]RCRT_N4?V'@/
M^?8?VEB_YS[>_P"'DEY_TT_S^-'_  \DO/\ II_G\:^(?+3^Y1Y:?W*/[#P'
M_/L/[2Q?\Y]O?\/)+S_II_G\:/\ AY)>?]-/\_C7Q#Y:?W*/+3^Y1_8> _Y]
MA_:6+_G/M[_AY)>?]-/\_C1_P\DO/^FG^?QKXA\M/[E'EI_<H_L/ ?\ /L/[
M2Q?\Y]K:I_P4@U66QDCL_DN/X/\ .:Y%?^"AGCW^*[KY7\M/6G;5K2.38"/_
M "Z1,LPQ4OML^IO^'AWCO_GO1_P\.\=_\]Z^5]J4;4JO[(P/_/I$_7\5_P _
M&?5'_#P[QW_SWH_X>'>._P#GO7ROM2C:E']D8'_GT@^OXK_GXSZH_P"'AWCO
M_GO6;KG_  4$^)5U!MTV_P#+>OFG:E.V^U..4X&+O[)"^O8E[S9[I_PWI\9_
M^@M_XY1_PWI\9O\ H+5X716W]G8/_GS'[D1]<Q'\[^]GNC?M[?&=?F_M;_QR
MOH[]B'XX?$;XN?$FXN/$EX\^G[*_/6^;;:R-7Z>?\$W?!\$?PQ37F3][+\BU
MX.=X?"83 RG"DDWIL>KEM6O7Q,5*;:7F?9]>/?M/^-(O!_PJU9FDV27$+(G_
M 'S7L-?#/_!33QN^E^"])TVRN/W[R-YL:5^<950^LXRG3\SZ_&U?8X><^MC\
MWMO_ !,KZ3^],S_^/5)38U_B_O4ZOW8_, HHHH **** "BBB@ IK?ZNG4V3_
M %>V@#ZZ_P"">7@=M>\4)K"Q_):O7ZDJNU<5\/\ _!,/PW]A^'^J7DR?O'==
MOTK[BK\9XAK>VQ\U_+H?HN4TU3PL6NNH4445\T>P%%%% !1110 4444 %%%%
M !1110 4444 %%%% !7FO[0%]-8_"C7F@^^]NR_^.UZ57EO[1TRQ?"?6MW_/
M%O\ T$UU877$03[K\S"OI2EZ'XE-_P A6_;^],W_ *%4E1M_R$K_ /ZZM_Z%
M4E?T"?E(4444 %%%% !1110 4V3_ %;TZHY/]8B_WGV4 ??7_!,'PRU]I>IZ
MJ_R+ _%?H;7R;_P3U\,_\(_\,IV\O9]HVO7UE7XCGE7VN/J/HC])RV')A8(:
MQV\U^7?_  4I\8+K?C?3+&VD_=6NY'_6OT]OI/*LYI/[J-7XH_M*>-&\9?%C
M6E:3>EK,R?\ CQKUN%J'M,6ZG\J.#/*O+AU#NSS-?N4445^L'PH4444 %%%%
M !1110 5#=-M@D:IJ:MO]NNH+/\ YZOLHO;<#]$O^":O@MCX=D\0?P?<K[SK
MYM_83\(_\(?\%K2W_O\ SU])5^'9Q6]OCJDO,_3,OI^SPT%Y!1117BGHC6&[
MBOSH_P""B/P!_L[_ (K+2;?SY;A_WVQ/N5^C-<UX^\'V?CCPM?Z1>0I/'<1,
MF'KU<MQTL!B8U5MU]#AQN&6*HNFS\'XVW?+_ !K3J]._:(^!FH? WQW/9R1O
M]BN'9TD_@KR]6W?,M?N%&K"O!5*;NF?F=2$J<W"2U0ZBBBMB HHHH **** "
MBBB@ J.2%&_V/^N=244 >A?#']HCQQ\(YT70[^1+=?OQR/OK[5^&?_!2GP]+
M:6ECXDCD^WM\KSU^=%1^2OWE^_7CXS*<)CM:L->Z/0P^/KX72#T['[>>"OCY
MX0\<6Z/:ZG#&S?\ +.21:[J+6K"X_P!7?6[_ .[*IK\$X=6UJU>-K?5IX-O_
M #S=J[CPO\?O&?A+R_)U*>?;_P ]';_&OD:W"3;O1J'O4L^TM4@?N"DBM]U]
MU25^2FD_\%$/B'I,:)Y'GI%78>&_^"F'BZ>Z?^TM)C2&O'GPQCXZI)_,]*.<
MX66]T?IW17YW:3_P4EU"2^VWEG''%76?\/&-,\O_ %<?^?QKCED./C]BYM'-
M<(_MGW+17PU_P\:TW_GG'_G\:3_AXQIG_/./_/XU']AX_P#Y]E?VIA/YS[FH
MKX"\2?\ !2#[/_R#;>.:N-U[_@I;XECMT;3],CDEK>'#V/G]FWJ9RS?"1^T?
MI:SJ@W-\M49M8L+?_6WT"?[TBBORHUK_ (*+_$/6(]JVGV5/^F=>4^,/VC/&
MWC?S/.OY[7=_SS=O\:]&CPKBIO\ >22_$Y*F>4(_ FS]</B)\?O"/P[T^2XO
M=3@F9?\ EG%(K5\N_$[_ (*4:"EC/9^&8Y/MGS;)Z_/&XU;6K_\ X^M6GNO^
MNCM5?RU^\WWZ^CPG"^$HV=9\S_#[CQZ^=5ZEU37*CT+XE?M">./BU=3_ -N7
M\[VC?<CC?97G<-NL4>W[_P#UTJ2BOK:5*G1CRTXV1X,YRJ/FF[L****U("BB
MB@ HHHH **** "FM(JTV2;;\J_.[?\\Z^DOV8_V.-7^,M[!JNK1R6N@HROO?
MY:Y<1BJ6$INK6=DC:C1GB)JG35V4_P!DK]F/5/C+XFM-4U&U>/0;5]\R2)]^
MOUH\,^&=/\(:':Z7IL"6MI;IL1%Z51\"^!=+^'OARTT?2K>."WMTV?(OWJZ>
MOQO-LTJ9E6N](+9'Z'@,##!PM]I[A117G7QJ^*FG?"CP5?ZI<SHETL3&&,_Q
M-7C4Z<JTU""NV>C.<:<7*6R/&OVUOVD+/X6>"Y]+T^[CDU.Z1D>.-_G2ORHO
M+R?5-2GOKB3?+*^_]Y_M5TOQ2^(VI_%;QI=Z]J$\CK+,VQ*YBOVO*<NAEV'4
M/M/=GYMCL6\95YNBV"BBBO</."BBB@ HHHH *T/"_AV\\8>)K#2;&.2=[AU1
M_+_WJRYF9(]L?SNS[*_1?]@G]F&+0[&/QMJT&][I-T,<B5Y>98Z&7X=U9;]%
MYG;@\++%U5!;=3Z+_9G^"=K\%_A_::>J1_:I45GDV?-]VO9::J[1@4ZOPZM6
MGB*DJM1W;/TNG3C2@H1V04445B:A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% "-7Y4_P#!0CX>OHGQ G\1>7L6X?\ UGYU^J]?'?\ P4@\
M$OXE^%\%Q;0YN('_ -97T?#^(>'Q\.TM#Q\UHJKAF^VI^7RMNCW4ZFK\LGE_
MQK\E.K]H/SH**** "BBB@ HHHH *&^Y110!]0?L _$Z+P/X\319'^;4'_P *
M_5^.3<B-_>K\)OA'KC>%?BIH.K>9L6WF7_T*OVY\ ^)H?%WA'3=3A^Y-$I_\
M=%?EO%6&]G7C7BM)+7U/MLCK<U)TWT.DHHHKX8^G"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.0T_<E4+5%%%?GY]8%%%% %:[LX]0M9()DWPR+M9&K\ROVS_ -CZ^\(ZI?\
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MNK5%5ML!"MG$OW:D6-4^[3J*!!1110,**** "BBB@ HHHH ***;YG\*_._\
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M]I:Y86+?<N'V5^R?[)?@]?!/P@TRQ5-GR[J_)#X1Z#+XC^*GAN&'[GVA=_\
MWU7[B^'-,AT?1+&UA38D42C_ ,=K\]XLKVA3H+KK]Q]7D-%7E5[&E(VV-VK\
MD/V[O'3^(_BA?Z/YF_[*_P!ROU5\::\GAKPKJ6I2?=MX6>OQ(^-FN?\ "4?%
M;6M45]_FS-_Z%7G\*T.>O.LUI%?B=>>U.6C&FNK.17M1117ZD?$A1110 444
M4 %%%% !4;?\?UI'_>F5/_'JDJ]X9T6?Q!XFTVUA^=UN(_\ T*I<E%78)7:2
M/V!_9#\))X7^$]@5CV?:$5__ !VO=*X_X5Z?_9?P_P!!M]FS;:Q\?\!KL*_
M,54=6O.;ZMGZM0A[.E&/9!1117*;A1110 4444 %%%% !1110 4444 %%%%
M!1110 5\_P#[95Q/;_"J[\F39N5__0:^@*^<?VW-4@T[X53^=_%N_P#0:]++
M5?%TUYG'C';#S]#\AO\ EZN_]]O_ $*I*C7_ (^IV_VVJ2OWD_+$%%%%!044
M44 %%%% !4+?\?UHO]Z9?_0JFJQHNCSZ]XCTVUM_O_:(_P#T*DW9-L%JTC]F
MOV8/#KZ#\)](\R/8\L2O_P".U[#7)?"ZU:S\ :#"_P!Y;2/_ -!KK:_G[$S]
MI7G+S?YGZO1CRTXQ71'E_P"T-XV;P+\-=3U!9/)_=,N__@-?BMX@O/[4\5:M
M???^T3,_F?\  J_3?_@HMXRCT_X52:/$_P#I$U?EQ9_\>_S??K].X5PZAA76
M>\G^!\7G=7FK*FMD34445]H?.!1110 4444 %%%% !6AX/A^V>.]"M?^>LRI
M_P"/5GUZ9^S7X17QA\5]&W)O^SS*_P#X\*PKU%2I2F]DG^1I2CSU(Q[L_8/X
M3^&QX7\$:;:[-C>4K$?\!KM*JZ>OEV-NG]V-1^E6J_GZI)SFY/J?JT(J,4D%
M%%%06%%%% 'D7[07P!TCXX>$Y["ZC2&]5/W5QLZ5^1/Q8^$.O?"#Q-=Z;J5A
M(EK$_P"YGV??K]TZ\X^+7P3\-?%S1Y+75[&.2?8=DVSD5]3D^=SRY^RJ:P?X
M'AYAEL<6N>&DC\08Y%ECW+]RG5[]^T)^QSXL^#U]/J5G!)?:.[ML2!-^Q?PK
MY_D6>UD\NZ@^RO\ \\Y*_6</B:6*IJI1E='PE6C.C+DJ*S'4445TF(4444 %
M%%% !1110 4444 %%%% !36C5J=10!&UNK4W['%4U%.X$/V.*C['%4U%*[ A
M6UB7[M2+&JTZB@ HHHH **** "BBB@ HHHH **** "BFM(J?>J:STW4]4NHX
M;&PGNGE_YYHSTGHKL%KHB%I%7YFK0\.^&]7\97T=KHMA)>RL^S]VE?2'P7_8
M-\7>//L^JZE(+737V_NY$K] OA#^S'X.^$MK UAIT;WRK\\_^U7R^8<08;!I
MQIOFE^![>%RFMB&G-<L3Y=_9F_X)^K936GB+Q=]YMK_89$_^M7W?H/AS3O"^
MFI8Z9:QVMLGW8TK45=HP*=7Y?CLPQ&/GSUI:=NA]MAL)2PL>6F@HHIC,JID_
M=KS3L*&M:U9^']-FOKZ9(+>%=SN]?DC^V7^T3<_&/QO/IFGSR0:38.R?NW^1
MZ^AO^"@/[2T6GV__  @^CS[[B7_7/"]?GE&K-YDDG^M;[]?IO#>4^SBL956K
MV_S/B\XQW._J]/9;CHXUBCVK3J**^^/E@HHHH **** "AFVT5L>!_ ^J_$KQ
M-;Z'I,;O<.Z[_P#OJIE)03E)V2'&+DU%=3U[]D#X W?QB\>6FJ30>9I-E+OF
M23[E?KWHNBVGA_2X;"QA2"VA7:D:=*\V_9T^#.G_  =\ 6=A;P>7>S1*]R_^
MUMKUNOQ?.LR>85WR_#'1'Z-EN#6$HJ_Q/<****^>/6"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS[XX>%HO%WPWUJUD3>RV[LG
M_?->@U1U2S&I:;<VQ_Y:(R5I2FZ=2,UT9%2*G!Q?4_ [5+66P\1ZM;S1['69
MD_\ 'JCKV3]K_P "M\/_ (O3V939]H=GKQNOW_#UEB*4:L=FC\JJP=*<H/HP
MHHHKH,@HHHH **** "BBB@"&ZD:*/S(_D=76OUW_ &'?'L'B3X.Z3IS2;[NU
M3YZ_(R2/='MK[4_X)K_$"5?&E_H=P^R+9\E?+\18;ZQ@G+^74]O**WLL2E_-
MH?IC1117XX?H04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !13695Y->??$KXT^&
M_ACI;W>I7T3.O_+-)%W4FTE=G5AL+7QE54</!RD]DE<[R::.WC9Y&"(O5FKP
M#XW_ +6_ASX6VLD-C+'J6H88"-'_ (J^6/CI^W!K/C0O8^&)Y-.L6^5Z^6]0
MU&YU:YDGNYY)Y7.YM[UYM3&+X:>I_0O"_A74J<N*SIV7\BW^;.^^*?QT\3?%
M+5KJXOKV1+69_D@W_<KS>BBO.U;YI.[/Z5PF#H8&DJ&&@HQ6R2L%%%%,[ HH
MHH **** "BBB@ HHHH **** "BBB@ HHI\:/))MC3>W^Q1<-M6,HKI/#OP_\
M0>)[Z.WL]-NB7;[_ );5]$> _P!@?Q5K#6]UJ4GV6T;YO+IQC.?PQ/G,RXBR
MO*5?&5XQ\KZGRK&KS2>7&F]Z[7PW\%O&'BIX_L.BSO$W_+397Z+^ _V*O 7A
MNW@GO]-%WJ"?\M,U[GHOA?3/#MFEM8VD,,*_W4%=D,'-_&S\9SCQ=PU*\,LH
MN;[RT7R/@[X;?\$];S6+>"^UO4_L2?>\C97U=X$_9I\%^"].@B_LJWNKE!_K
MW2O6U7;3J[H4*=/X4?B&<<9YUG7NXBNU'LM%^!3T^PMM-A$-M"D,:_PI5RBB
MN@^(;<G=L****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!^4'_  4*\;-XB^)6F+;R?Z/L_P!77RRJ[:[+XH>(-1\;ZQ!>202/
MM_V&KD?L=]_SZ2?]\5^]X&BL-AH4NR/RS%5'6K2GW&T4[['??\^DG_?%'V.^
M_P"?23_OBN[F7<Y=1M%.^QWW_/I)_P!\4?8[[_GTD_[XHYEW#4;13OL=]_SZ
M2?\ ?%'V.^_Y])/^^*.9=PU&T4[['??\^DG_ 'Q1]COO^?23_OBCF7<-1M%.
M^QWW_/I)_P!\4?8[[_GTD_[XHYEW#4;13OL=]_SZ2?\ ?%'V.^_Y])/^^*.9
M=PU&T4[['??\^DG_ 'Q1]COO^?23_OBCF7<-1M%.^QWW_/I)_P!\4?8[[_GT
MD_[XHYEW#4;13OL=]_SZ2?\ ?%'V.^_Y])/^^*.9=PU&T4[['??\^DG_ 'Q1
M]COO^?23_OBCF7<-1M%.^QWW_/I)_P!\4?8[[_GTD_[XHYEW#4;13OL=]_SZ
M2?\ ?%'V.^_Y])/^^*.9=PU&T4[['??\^DG_ 'Q4EOI.IWDGEV]C(\O^Y1S+
MJPU[$-%:G_"%^)?^@3/_ -\-3H_ _BB63;'HL^__ *YM4^TAW7WH?++L9-%=
M,OPE\=-]WPU/\W^PU;&F_L[_ !*U*:-?^$7N$B;_ ):?-4/$48ZN:^]&JHU7
MM%G [O>F[E_OU]!>'_V)?&>N74<=Q826J?\ /3YO\*]<\-?\$P;O5(TDU'6O
ML7_ /_K5YU7-\#1^.JCJIY?B:FT&?#LEPJ_\LW?_ '$K6\.^%]7\877V72[2
M=Y6_V&K]0? /_!/_ ,)>$A M\Z:IM^]O3_ZU>Z>'O@IX,\+;/[/T&TA=?X_+
M6O Q'%6'A=48N3_ ]2ED=66M25C\R?AA^P=X^\6W\$FLVCVFE-]]_P#(K[:^
M#W[#7@OX7W=O>[/MMVNUV\Q/XJ^E8X4@CVHFQ1V6I:^-QF?8S&)QYN6+Z(^B
MP^5X?#ZVN_,JV-C;V$'E6T*0Q+_!&FT5:HHKYWU/7VT04444 -9MJYK\L/\
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MCV_9)/\ OBG?8[[_ )])/^^*_;VUW/S74;13OL=]_P ^DG_?%'V.^_Y])/\
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MQF-NJD[+LCZ##Y?A\/9QCJ06UO%:QB.*-(E'\*5/117BGI!1110 5X%^UO\
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M=_\ @%?LGY*?W!436%L_WH(V_P" "NF/%6,7Q13,)9'AWLV?C/\ \,B^/?\
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M /AE7X<_] */\Z/^&5?AS_T H_SKV"BCZ[B?^?C^]A]5H_R(\>;]E/X;M_S
M8_SKK/!7PE\,_#]BVB6"6K>U=K143Q5>HN6<VUZE1H4H.\8I,****Y3<****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD/B!\+_#WQ,L([37[,7M
MO'RJ$UU]%7"<J<N:#LR914ERR5T>/?\ #*GPX_Z ,?YTO_#*OPY_Z 4?YU[!
M175]=Q/_ #\?WLP^JT?Y$>/_ /#*OPY_Z 4?YT?\,J_#G_H!1_G7L%%'UW$_
M\_'][#ZK1_D1X_\ \,J_#G_H!1_G1_PRK\.?^@%'^=>P44?7<3_S\?WL/JM'
M^1'C_P#PRK\.?^@%'^='_#*OPY_Z 4?YU[!11]=Q/_/Q_>P^JT?Y$>/_ /#*
MOPY_Z 4?YU;T7]FWP#X?U 7ECHL<%PO\=>JT5+QF):LZC^]@L-16J@B*WA6W
MA2-/NKTJ*^LX[ZUDMYANBD7:PJU17)YG2>0W7[+GP\O+EYYM$C>5WWL<TW_A
ME7X<_P#0"C_.O8**[/KF)_Y^/[V<WU:C_(CQ_P#X95^'/_0"C_.C_AE7X<_]
M */\Z]@HI_7<3_S\?WL/JM'^1'C_ /PRK\.?^@%'^='_  RK\.?^@%'^=>P4
M4?7<3_S\?WL/JM'^1'C_ /PRK\.?^@%'^='_  RK\.?^@%'^=>P44?7<3_S\
M?WL/JM'^1'C_ /PRK\.?^@%'^='_  RK\.?^@%'^=>P44?7<3_S\?WL/JM'^
M1'CC?LH_#=_E.@QG\:] \(^!=%\$V?V71[-+6+T%='16=3$UJJY9S;7J7"C3
MIN\8I!1117,;!1110 4444 %%%% !1110 4444 %1-!')]Y%;\*EHH P-6\$
MZ-K2N+JP@DW?],UKSW7OV5?ASXF_X_M!CD_&O8:*Z*>(K4M:<VOF92HTY_%%
M,^9M<_8'^&5_,CV.DI9+_'_G%>>:Q_P3JT62[G:S,<<7\'^<5]N45Z%/.,=3
MT55OU..67X:>\$?G9J7_  39U!YW^SW\:1?Y]JX_5?\ @F9XU:X_T/5HTBK]
M0Z*]"/$F/C]I?<<SR?"/[)^5%U_P32^(=K#OCU..<_\ /.L/_AWW\1O^>E?K
MG4>Q?[E;KBC'K>WW&4LEPS[GY(?\.^_B)_STH_X=]_$3_GI7ZW[%_N4;%_N5
M7^M.-[+[B?[$PW=GY(?\.^_B)_STH_X=]_$3_GI7ZW[%_N4;%_N4?ZTXWLON
M#^Q,-W9^2'_#OOXB?\]*/^'??Q&_O_\ CE?K?L7^Y1L7^Y1_K3C>R^X/[$PW
M=GY56?\ P34^(=TF^34XX#5ZS_X)F>.EN$\[5H_*K]2Z*R?$^8/JON-/[&PO
M8_.'_AVOK'[O_B81_P"W_G%=SIO_  3GTQ8X/M4D<C_Q_P"<5]RT5RSX@Q\_
MMFT<JPL?LGRII7_!/GX?6^S[9:)/_?KL]+_8N^%.DR+);^'HT8>]>\45P2S/
M&S^*K+[SJC@L-':"//-%^!?@W09(Y+/2((V3[OR+7;PZ79VZXBM(4_W(U%7*
M*X)U)U'><KG5&G&&D58C6-5^ZE2445F6%%%% !1110 4444 %%%% &)XF\)Z
M;XNTN33M3@\^TD^]'7FT?[)_PWBCVKH4?YU[)1713Q%:DK0FTO4QG1IU'><;
ML\?_ .&5?AS_ - */\Z/^&5?AS_T H_SKV"BM?KN)_Y^/[V1]5H_R(\?_P"&
M5?AS_P! */\ .C_AE7X<_P#0"C_.O8**/KN)_P"?C^]A]5H_R(\?_P"&5?AS
M_P! */\ .C_AE7X<_P#0"C_.O8**/KN)_P"?C^]A]5H_R(\?_P"&5?AS_P!
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MZ@]YJ=W)/<-_MM6+17!*4ZGQNY^]95P_EN2P4,%14?/K]X4444K6/H@HHHH
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MNT?=7X&-HWAC3= M!;65I'!".VT5KJJKTIU%=!\1.<JDG*;NV%%%%! 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;O>K7-)7BKH\_$9E@\(KXBK&/JT>6T;O>OIOPQ^PAX[O9$_M:T^RI7L7A/\
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ML45LM-$?'UL16Q$N>K-R?FQH7;TIU%%!@%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKZYKT'PW^P1XON)$_M2/R$K]+$C6/[J[:EK98.FO,^/Q/BQG=96IPA#T3O\
MBSXAT7_@G=I,WD?;KMT_OUWVD?L$^!-+FCE/F3LO]^OJ"BMHX>E'51/D,1QS
MQ!B?BQ4EZ:'EVB?L\^#M%C15TR%]O_3-:[FW\+:1:PI''IMJBKT_<K6Q16ZB
MD?)XC,,7BGS5JKD_-LIQZ?;6W^KAC3_=2K07;TIU%4<#;>X4444""BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNMK?[=3]>7\OY'5_Q!VKUQ2^X_7;_A<GA/>5_M:'Y?\ ;6D7XQ>%6_YBT/\
MWVM?CO\ \)IKG_02G_[[I?\ A--;_P"@E<?]_&J?KWD>A_Q!^E_T$_@?K9>_
MM*> ["Z>VEUF,2+47_#3WP^_Z#<?Y5^1%QJUY<S;Y;F=W_WS47]H7'_/Q)_W
MW4_7WV.^/A!EUES5Y7/UGU+]L#X8:5)LFUU0WTJK_P -K?"G_H/?^.5^3DDG
MG?ZQW>F?)4O'3Z6.R/A#DUK2JU+^J_R/U0U7]N;X<VK!;34OM*_WQ5!?V\/
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MABPF$T6DV^]?]A:W%\+Z4O33+0?]L5K6HJ[(\>IBL14=YU&_FS.70[!>190
M_P"XM3K86R](8Q_P&K5%,P<Y/=LB6,+]U<5+1100%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
64444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
